<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540592</url>
  </required_header>
  <id_info>
    <org_study_id>110847</org_study_id>
    <nct_id>NCT00540592</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A</brief_title>
  <official_title>Observer Blind Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK576389A With Various Formulations in Adults Aged 65 Years and Above</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      In order to find the formulation leading to a maximal increase of the immune response while
      maintaining an acceptable safety profile, this study is designed to evaluate the
      immunogenicity, safety and reactogenicity of the different formulations of GSK Biologicals'
      influenza vaccine administered in adults aged 65 years and older compared to Fluarix.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are 10 parallel groups: 9 observer blinded groups with subjects 65 years and older
      receiving an investigational vaccine or Fluarix, and 1 open group with subjects between 18
      and 40 years old receiving Fluarix. CMI response will be determined for a subset only.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haemagglutination Inhibition (HI) Antibody Titers</measure>
    <time_frame>At Day 21</time_frame>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs) against each of the 3 vaccine strains in greater than or equal to 65 years age groups only. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Titers at Day 0 and Day 21</measure>
    <time_frame>At Day 0 and 21</time_frame>
    <description>Antibody titers were expressed as GMTs in all the vaccine groups. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Titers at Day 180</measure>
    <time_frame>At Day 180</time_frame>
    <description>Antibody titers were expressed as GMTs in all the vaccine groups. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroconverted to HI Antibodies at Day 21</measure>
    <time_frame>At Day 21</time_frame>
    <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroconverted to HI Antibodies at Day 180</measure>
    <time_frame>At Day 180</time_frame>
    <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Seroconversion Factors at Day 21</measure>
    <time_frame>At Day 21</time_frame>
    <description>Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Seroconversion Factors at Day 180</measure>
    <time_frame>At Day 180</time_frame>
    <description>Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21</measure>
    <time_frame>At Day 0 and 21</time_frame>
    <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroprotected to HI Antibodies at Day 180</measure>
    <time_frame>At Day 180</time_frame>
    <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>The markers assessed were Cluster of Differentiation 4-All doubles i.e. CD4-All doubles, CD4-CD40Ligand(L), CD4-interferon gamma (CD4-IFNγ), CD4-interleukin 2 (CD4-IL2) and CD4-tumor necrosis factor alpha (CD4-TNFα). The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180</measure>
    <time_frame>At Day 180</time_frame>
    <description>The markers assessed were CD4-All doubles, CD4-CD40L, CD4-IFNγ, CD4-IL2 and CD4-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>The markers assessed were Cluster of Differentiation 8-All doubles i.e. CD8-All doubles, CD8-CD40L, CD8-IFNγ, CD8-IL2 and CD8-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180</measure>
    <time_frame>At Day 180</time_frame>
    <description>The markers assessed were CD8-All doubles, CD8-CD40L, CD8-IFNγ, CD8-IL2 and CD8-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</measure>
    <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
    <description>Grade 3 ecchymosis, pain, redness and swelling was greater than 100 millimeter (mm) i.e. &gt; 100 mm and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade. Any for ecchymosis, redness and swelling was &gt;20mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited Local AEs</measure>
    <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
    <description>Duration was defined as number of days with any grade of local symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</measure>
    <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
    <description>Any Fever was defined as axillary temperature greater than or equal to 38.0 degree centigrade i.e.≥ 38.0°C, grade 3 fever was axillary temperature &gt;40°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a general symptom that prevented normal activity. Related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited General AEs</measure>
    <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
    <description>Duration was defined as number of days with any grade of general symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</measure>
    <time_frame>During a 21-day follow-up period (Day 0-20) after vaccination</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20</measure>
    <time_frame>Between Day 0 and Day 20 after vaccination</time_frame>
    <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a symptom that prevented normal activity. Related was a symptom assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179</measure>
    <time_frame>Between Day 21 and Day 179 after vaccination</time_frame>
    <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a symptom that prevented normal activity. Related was a symptom assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20</measure>
    <time_frame>Between Day 0 and Day 20 after vaccination</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179</measure>
    <time_frame>Between Day 21 and Day 179 after vaccination</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">2007</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Influenza vaccine GSK576389A formulation 1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza vaccine GSK576389A formulation 2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza vaccine GSK576389A formulation 3 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza vaccine GSK576389A formulation 4 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza vaccine GSK576389A formulation 5 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza vaccine GSK576389A formulation 6 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza vaccine GSK576389A formulation 7 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza vaccine GSK576389A formulation 8 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix elderly Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix young Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GlaxoSmithKline Biologicals' influenza vaccine GSK576389A</intervention_name>
    <description>Single dose, Intramuscular injection, 8 different formulations were tested (one per group)</description>
    <arm_group_label>Influenza vaccine GSK576389A formulation 5 Group</arm_group_label>
    <arm_group_label>Influenza vaccine GSK576389A formulation 4 Group</arm_group_label>
    <arm_group_label>Influenza vaccine GSK576389A formulation 1 Group</arm_group_label>
    <arm_group_label>Influenza vaccine GSK576389A formulation 3 Group</arm_group_label>
    <arm_group_label>Influenza vaccine GSK576389A formulation 2 Group</arm_group_label>
    <arm_group_label>Influenza vaccine GSK576389A formulation 7 Group</arm_group_label>
    <arm_group_label>Influenza vaccine GSK576389A formulation 6 Group</arm_group_label>
    <arm_group_label>Influenza vaccine GSK576389A formulation 8 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix</intervention_name>
    <description>Single dose, Intramuscular injection</description>
    <arm_group_label>Fluarix elderly Group</arm_group_label>
    <arm_group_label>Fluarix young Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol should be enrolled in the study.

          -  A male or female aged 18-40 years old or 65 years or older at the time of the
             vaccination.

          -  Written informed consent obtained from the subject.

          -  Free of an acute aggravation of the health status as established by clinical
             evaluation (medical history and medical history directed examination) before entering
             into the study.

          -  If the subject is female, she must be of non-childbearing potential or if she is of
             childbearing potential, she must practice adequate contraception for 30 days prior to
             vaccination, have a negative pregnancy test and continue such precautions for 2 months
             after completion of the vaccination series.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days prior to vaccination, or planned use during the study
             period.

          -  Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or
             4 weeks (for live vaccines) prior to enrolment in this study.

          -  Planned administration of a vaccine not foreseen by the study protocol during the
             entire study period.

          -  Planned administration of an influenza vaccine other than the study vaccines during
             the entire study period.

          -  Vaccination against influenza since January 2007 (with 2007/2008 or 2006/2007
             influenza vaccine).

          -  Administration of more than 14 days of immunosuppressants or other immune-modifying
             drugs within 6 months prior to the administration of the study vaccine.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination

          -  Hypersensitivity to a previous dose of influenza vaccine.

          -  Allergy to any component of the vaccine.

          -  Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality.

          -  Acute disease at the time of enrolment. (Acute disease is defined as the presence of a
             moderate or severe illness with or without fever. All vaccines can be administered to
             persons with a minor illness such as diarrhoea, mild upper respiratory infection with
             or without low-grade febrile illness, i.e. axillary temperature&lt;37.5ºC (99.5ºF).

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first administration of the study vaccine or planned administration
             during the study.

          -  Any medical conditions in which IM injections are contraindicated.

          -  Lactating female or female planning to become pregnant or to discontinue contraceptive
             precautions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gueglingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>74363</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rudersberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>73635</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weinheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rhaunen</city>
        <state>Rheinland-Pfalz</state>
        <zip>55624</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wolmirstedt</city>
        <state>Sachsen-Anhalt</state>
        <zip>39326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freital</city>
        <state>Sachsen</state>
        <zip>01705</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3011 EN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eskilstuna</city>
        <zip>SE-631 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karlskrona</city>
        <zip>SE-371 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG2 0TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buckshaw Village, Chorley</city>
        <state>Lancashire</state>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clydebank, Glasgow</city>
        <zip>G81 2DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edgbaston, Birmingham</city>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waterloo, Liverpool</city>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <results_first_submitted>April 26, 2012</results_first_submitted>
  <results_first_submitted_qc>April 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 30, 2012</results_first_posted>
  <disposition_first_submitted>May 20, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 28, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 30, 2009</disposition_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza vaccine GSK576389A</keyword>
  <keyword>Influenza infection</keyword>
  <keyword>Fluarix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>110847</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110847</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110847</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110847</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110847</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110847</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110847</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="P2">
          <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="P3">
          <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="P4">
          <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="P5">
          <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="P6">
          <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="P7">
          <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="P8">
          <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="P9">
          <title>Fluarix Elderly Group</title>
          <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
        </group>
        <group group_id="P10">
          <title>Fluarix Young Group</title>
          <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="202"/>
                <participants group_id="P3" count="202"/>
                <participants group_id="P4" count="202"/>
                <participants group_id="P5" count="199"/>
                <participants group_id="P6" count="198"/>
                <participants group_id="P7" count="198"/>
                <participants group_id="P8" count="199"/>
                <participants group_id="P9" count="200"/>
                <participants group_id="P10" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed at Day 180</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="201"/>
                <participants group_id="P3" count="197"/>
                <participants group_id="P4" count="197"/>
                <participants group_id="P5" count="195"/>
                <participants group_id="P6" count="198"/>
                <participants group_id="P7" count="196"/>
                <participants group_id="P8" count="193"/>
                <participants group_id="P9" count="198"/>
                <participants group_id="P10" count="189"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="201"/>
                <participants group_id="P3" count="201"/>
                <participants group_id="P4" count="201"/>
                <participants group_id="P5" count="198"/>
                <participants group_id="P6" count="198"/>
                <participants group_id="P7" count="198"/>
                <participants group_id="P8" count="198"/>
                <participants group_id="P9" count="199"/>
                <participants group_id="P10" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="B2">
          <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="B3">
          <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="B4">
          <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="B5">
          <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="B6">
          <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="B7">
          <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="B8">
          <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="B9">
          <title>Fluarix Elderly Group</title>
          <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
        </group>
        <group group_id="B10">
          <title>Fluarix Young Group</title>
          <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="204"/>
            <count group_id="B2" value="202"/>
            <count group_id="B3" value="202"/>
            <count group_id="B4" value="202"/>
            <count group_id="B5" value="199"/>
            <count group_id="B6" value="198"/>
            <count group_id="B7" value="198"/>
            <count group_id="B8" value="199"/>
            <count group_id="B9" value="200"/>
            <count group_id="B10" value="203"/>
            <count group_id="B11" value="2007"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.7" spread="5.75"/>
                    <measurement group_id="B2" value="72.6" spread="5.16"/>
                    <measurement group_id="B3" value="72.4" spread="5.62"/>
                    <measurement group_id="B4" value="72.9" spread="6.09"/>
                    <measurement group_id="B5" value="72.6" spread="5.66"/>
                    <measurement group_id="B6" value="72.7" spread="5.56"/>
                    <measurement group_id="B7" value="72.6" spread="5.67"/>
                    <measurement group_id="B8" value="73.0" spread="6.03"/>
                    <measurement group_id="B9" value="72.7" spread="5.43"/>
                    <measurement group_id="B10" value="27.4" spread="6.25"/>
                    <measurement group_id="B11" value="68.11" spread="14.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="100"/>
                    <measurement group_id="B5" value="89"/>
                    <measurement group_id="B6" value="102"/>
                    <measurement group_id="B7" value="96"/>
                    <measurement group_id="B8" value="95"/>
                    <measurement group_id="B9" value="90"/>
                    <measurement group_id="B10" value="103"/>
                    <measurement group_id="B11" value="984"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="102"/>
                    <measurement group_id="B5" value="110"/>
                    <measurement group_id="B6" value="96"/>
                    <measurement group_id="B7" value="102"/>
                    <measurement group_id="B8" value="104"/>
                    <measurement group_id="B9" value="110"/>
                    <measurement group_id="B10" value="100"/>
                    <measurement group_id="B11" value="1023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Haemagglutination Inhibition (HI) Antibody Titers</title>
        <description>Antibody titers were expressed as Geometric mean titers (GMTs) against each of the 3 vaccine strains in greater than or equal to 65 years age groups only. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
        <time_frame>At Day 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Haemagglutination Inhibition (HI) Antibody Titers</title>
          <description>Antibody titers were expressed as Geometric mean titers (GMTs) against each of the 3 vaccine strains in greater than or equal to 65 years age groups only. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="192"/>
                <count group_id="O3" value="189"/>
                <count group_id="O4" value="194"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="193"/>
                <count group_id="O7" value="192"/>
                <count group_id="O8" value="189"/>
                <count group_id="O9" value="188"/>
                <count group_id="O10" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.3" lower_limit="69.7" upper_limit="97.1"/>
                    <measurement group_id="O2" value="102.2" lower_limit="87.0" upper_limit="119.9"/>
                    <measurement group_id="O3" value="98.2" lower_limit="84.3" upper_limit="114.3"/>
                    <measurement group_id="O4" value="91.7" lower_limit="76.9" upper_limit="109.3"/>
                    <measurement group_id="O5" value="113.2" lower_limit="96.0" upper_limit="133.6"/>
                    <measurement group_id="O6" value="114.4" lower_limit="97.1" upper_limit="134.8"/>
                    <measurement group_id="O7" value="78.5" lower_limit="65.9" upper_limit="93.5"/>
                    <measurement group_id="O8" value="111.8" lower_limit="93.3" upper_limit="134.0"/>
                    <measurement group_id="O9" value="59.6" lower_limit="49.6" upper_limit="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.2" lower_limit="238.8" upper_limit="319.6"/>
                    <measurement group_id="O2" value="350.2" lower_limit="298.0" upper_limit="411.4"/>
                    <measurement group_id="O3" value="351.3" lower_limit="304.8" upper_limit="404.8"/>
                    <measurement group_id="O4" value="309.2" lower_limit="264.9" upper_limit="361.0"/>
                    <measurement group_id="O5" value="331.1" lower_limit="289.6" upper_limit="378.6"/>
                    <measurement group_id="O6" value="438.1" lower_limit="379.7" upper_limit="505.4"/>
                    <measurement group_id="O7" value="263.3" lower_limit="225.3" upper_limit="307.7"/>
                    <measurement group_id="O8" value="347.5" lower_limit="296.4" upper_limit="407.3"/>
                    <measurement group_id="O9" value="186.7" lower_limit="158.0" upper_limit="220.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.1" lower_limit="129.1" upper_limit="167.6"/>
                    <measurement group_id="O2" value="163.1" lower_limit="142.5" upper_limit="186.6"/>
                    <measurement group_id="O3" value="172.1" lower_limit="149.9" upper_limit="197.6"/>
                    <measurement group_id="O4" value="152.4" lower_limit="134.4" upper_limit="172.7"/>
                    <measurement group_id="O5" value="181.4" lower_limit="158.9" upper_limit="207.1"/>
                    <measurement group_id="O6" value="202.0" lower_limit="179.7" upper_limit="227.1"/>
                    <measurement group_id="O7" value="155.7" lower_limit="134.8" upper_limit="179.8"/>
                    <measurement group_id="O8" value="174.6" lower_limit="152.0" upper_limit="200.7"/>
                    <measurement group_id="O9" value="153.0" lower_limit="135.2" upper_limit="173.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Titers at Day 0 and Day 21</title>
        <description>Antibody titers were expressed as GMTs in all the vaccine groups. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
        <time_frame>At Day 0 and 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody Titers at Day 0 and Day 21</title>
          <description>Antibody titers were expressed as GMTs in all the vaccine groups. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="192"/>
                <count group_id="O3" value="189"/>
                <count group_id="O4" value="194"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="193"/>
                <count group_id="O7" value="192"/>
                <count group_id="O8" value="189"/>
                <count group_id="O9" value="188"/>
                <count group_id="O10" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="9.3" upper_limit="12.2"/>
                    <measurement group_id="O2" value="10.8" lower_limit="9.4" upper_limit="12.4"/>
                    <measurement group_id="O3" value="10.1" lower_limit="8.8" upper_limit="11.5"/>
                    <measurement group_id="O4" value="10.6" lower_limit="9.3" upper_limit="12.1"/>
                    <measurement group_id="O5" value="12.0" lower_limit="10.3" upper_limit="14.0"/>
                    <measurement group_id="O6" value="9.9" lower_limit="8.6" upper_limit="11.3"/>
                    <measurement group_id="O7" value="10.2" lower_limit="8.9" upper_limit="11.7"/>
                    <measurement group_id="O8" value="10.3" lower_limit="9.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="10.7" lower_limit="9.2" upper_limit="12.4"/>
                    <measurement group_id="O10" value="21.3" lower_limit="17.1" upper_limit="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.3" lower_limit="69.7" upper_limit="97.1"/>
                    <measurement group_id="O2" value="102.2" lower_limit="87.0" upper_limit="119.9"/>
                    <measurement group_id="O3" value="98.2" lower_limit="84.3" upper_limit="114.3"/>
                    <measurement group_id="O4" value="91.7" lower_limit="76.9" upper_limit="109.3"/>
                    <measurement group_id="O5" value="113.2" lower_limit="96.0" upper_limit="133.6"/>
                    <measurement group_id="O6" value="114.4" lower_limit="97.1" upper_limit="134.8"/>
                    <measurement group_id="O7" value="78.5" lower_limit="65.9" upper_limit="93.5"/>
                    <measurement group_id="O8" value="111.8" lower_limit="93.3" upper_limit="134.0"/>
                    <measurement group_id="O9" value="59.6" lower_limit="49.6" upper_limit="71.7"/>
                    <measurement group_id="O10" value="271.6" lower_limit="224.6" upper_limit="328.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.9" lower_limit="49.5" upper_limit="72.4"/>
                    <measurement group_id="O2" value="51.2" lower_limit="41.9" upper_limit="62.4"/>
                    <measurement group_id="O3" value="44.4" lower_limit="36.5" upper_limit="54.0"/>
                    <measurement group_id="O4" value="65.7" lower_limit="53.7" upper_limit="80.4"/>
                    <measurement group_id="O5" value="61.1" lower_limit="50.6" upper_limit="73.8"/>
                    <measurement group_id="O6" value="55.8" lower_limit="46.2" upper_limit="67.4"/>
                    <measurement group_id="O7" value="54.6" lower_limit="44.5" upper_limit="67.0"/>
                    <measurement group_id="O8" value="57.8" lower_limit="47.1" upper_limit="70.9"/>
                    <measurement group_id="O9" value="61.0" lower_limit="49.8" upper_limit="74.7"/>
                    <measurement group_id="O10" value="47.8" lower_limit="39.2" upper_limit="58.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.2" lower_limit="238.8" upper_limit="319.6"/>
                    <measurement group_id="O2" value="350.2" lower_limit="298.0" upper_limit="411.4"/>
                    <measurement group_id="O3" value="351.3" lower_limit="304.8" upper_limit="404.8"/>
                    <measurement group_id="O4" value="309.2" lower_limit="264.9" upper_limit="361.0"/>
                    <measurement group_id="O5" value="331.1" lower_limit="289.6" upper_limit="378.6"/>
                    <measurement group_id="O6" value="438.1" lower_limit="379.7" upper_limit="505.4"/>
                    <measurement group_id="O7" value="263.3" lower_limit="225.3" upper_limit="307.7"/>
                    <measurement group_id="O8" value="347.5" lower_limit="296.4" upper_limit="407.3"/>
                    <measurement group_id="O9" value="186.7" lower_limit="158.0" upper_limit="220.7"/>
                    <measurement group_id="O10" value="380.2" lower_limit="331.6" upper_limit="435.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="49.8" upper_limit="68.9"/>
                    <measurement group_id="O2" value="53.7" lower_limit="45.7" upper_limit="63.2"/>
                    <measurement group_id="O3" value="57.0" lower_limit="48.2" upper_limit="67.5"/>
                    <measurement group_id="O4" value="62.6" lower_limit="53.3" upper_limit="73.4"/>
                    <measurement group_id="O5" value="77.8" lower_limit="66.0" upper_limit="91.7"/>
                    <measurement group_id="O6" value="62.9" lower_limit="53.9" upper_limit="73.4"/>
                    <measurement group_id="O7" value="58.2" lower_limit="49.0" upper_limit="69.1"/>
                    <measurement group_id="O8" value="62.6" lower_limit="53.0" upper_limit="74.0"/>
                    <measurement group_id="O9" value="66.5" lower_limit="56.5" upper_limit="78.3"/>
                    <measurement group_id="O10" value="23.4" lower_limit="19.1" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.1" lower_limit="129.1" upper_limit="167.6"/>
                    <measurement group_id="O2" value="163.1" lower_limit="142.5" upper_limit="186.6"/>
                    <measurement group_id="O3" value="172.1" lower_limit="149.9" upper_limit="197.6"/>
                    <measurement group_id="O4" value="152.4" lower_limit="134.4" upper_limit="172.7"/>
                    <measurement group_id="O5" value="181.4" lower_limit="158.9" upper_limit="207.1"/>
                    <measurement group_id="O6" value="202.0" lower_limit="179.7" upper_limit="227.1"/>
                    <measurement group_id="O7" value="155.7" lower_limit="134.8" upper_limit="179.8"/>
                    <measurement group_id="O8" value="174.6" lower_limit="152.0" upper_limit="200.7"/>
                    <measurement group_id="O9" value="153.0" lower_limit="135.2" upper_limit="173.1"/>
                    <measurement group_id="O10" value="281.9" lower_limit="241.7" upper_limit="328.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Titers at Day 180</title>
        <description>Antibody titers were expressed as GMTs in all the vaccine groups. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
        <time_frame>At Day 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 180.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody Titers at Day 180</title>
          <description>Antibody titers were expressed as GMTs in all the vaccine groups. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 180.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="186"/>
                <count group_id="O3" value="180"/>
                <count group_id="O4" value="184"/>
                <count group_id="O5" value="180"/>
                <count group_id="O6" value="187"/>
                <count group_id="O7" value="187"/>
                <count group_id="O8" value="174"/>
                <count group_id="O9" value="181"/>
                <count group_id="O10" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6" lower_limit="25.8" upper_limit="36.3"/>
                    <measurement group_id="O2" value="35.1" lower_limit="29.7" upper_limit="41.5"/>
                    <measurement group_id="O3" value="36.3" lower_limit="30.7" upper_limit="42.8"/>
                    <measurement group_id="O4" value="32.5" lower_limit="27.6" upper_limit="38.2"/>
                    <measurement group_id="O5" value="40.4" lower_limit="34.1" upper_limit="47.9"/>
                    <measurement group_id="O6" value="33.7" lower_limit="28.6" upper_limit="39.7"/>
                    <measurement group_id="O7" value="29.9" lower_limit="25.5" upper_limit="35.0"/>
                    <measurement group_id="O8" value="39.8" lower_limit="33.6" upper_limit="47.2"/>
                    <measurement group_id="O9" value="23.7" lower_limit="20.3" upper_limit="27.7"/>
                    <measurement group_id="O10" value="114.7" lower_limit="91.8" upper_limit="143.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.5" lower_limit="112.6" upper_limit="153.5"/>
                    <measurement group_id="O2" value="139.8" lower_limit="118.1" upper_limit="165.5"/>
                    <measurement group_id="O3" value="133.4" lower_limit="112.7" upper_limit="158.1"/>
                    <measurement group_id="O4" value="134.0" lower_limit="113.1" upper_limit="158.7"/>
                    <measurement group_id="O5" value="144.7" lower_limit="124.9" upper_limit="167.5"/>
                    <measurement group_id="O6" value="181.4" lower_limit="156.5" upper_limit="210.3"/>
                    <measurement group_id="O7" value="118.2" lower_limit="99.8" upper_limit="140.0"/>
                    <measurement group_id="O8" value="145.3" lower_limit="121.9" upper_limit="173.2"/>
                    <measurement group_id="O9" value="92.5" lower_limit="78.7" upper_limit="108.6"/>
                    <measurement group_id="O10" value="193.2" lower_limit="163.5" upper_limit="228.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" lower_limit="81.2" upper_limit="106.0"/>
                    <measurement group_id="O2" value="94.3" lower_limit="81.6" upper_limit="109.1"/>
                    <measurement group_id="O3" value="100.9" lower_limit="87.7" upper_limit="116.1"/>
                    <measurement group_id="O4" value="87.4" lower_limit="75.9" upper_limit="100.6"/>
                    <measurement group_id="O5" value="109.2" lower_limit="94.9" upper_limit="125.6"/>
                    <measurement group_id="O6" value="111.4" lower_limit="97.2" upper_limit="127.6"/>
                    <measurement group_id="O7" value="89.0" lower_limit="76.1" upper_limit="104.0"/>
                    <measurement group_id="O8" value="97.7" lower_limit="84.7" upper_limit="112.7"/>
                    <measurement group_id="O9" value="96.6" lower_limit="83.8" upper_limit="111.3"/>
                    <measurement group_id="O10" value="132.4" lower_limit="110.2" upper_limit="159.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroconverted to HI Antibodies at Day 21</title>
        <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
        <time_frame>At Day 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroconverted to HI Antibodies at Day 21</title>
          <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="189"/>
                <count group_id="O4" value="194"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="193"/>
                <count group_id="O7" value="192"/>
                <count group_id="O8" value="189"/>
                <count group_id="O9" value="187"/>
                <count group_id="O10" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="138"/>
                    <measurement group_id="O3" value="154"/>
                    <measurement group_id="O4" value="130"/>
                    <measurement group_id="O5" value="142"/>
                    <measurement group_id="O6" value="151"/>
                    <measurement group_id="O7" value="129"/>
                    <measurement group_id="O8" value="146"/>
                    <measurement group_id="O9" value="99"/>
                    <measurement group_id="O10" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="124"/>
                    <measurement group_id="O3" value="141"/>
                    <measurement group_id="O4" value="104"/>
                    <measurement group_id="O5" value="124"/>
                    <measurement group_id="O6" value="142"/>
                    <measurement group_id="O7" value="110"/>
                    <measurement group_id="O8" value="131"/>
                    <measurement group_id="O9" value="69"/>
                    <measurement group_id="O10" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="45"/>
                    <measurement group_id="O6" value="79"/>
                    <measurement group_id="O7" value="50"/>
                    <measurement group_id="O8" value="55"/>
                    <measurement group_id="O9" value="47"/>
                    <measurement group_id="O10" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroconverted to HI Antibodies at Day 180</title>
        <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
        <time_frame>At Day 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 180.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroconverted to HI Antibodies at Day 180</title>
          <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 180.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="186"/>
                <count group_id="O3" value="180"/>
                <count group_id="O4" value="184"/>
                <count group_id="O5" value="180"/>
                <count group_id="O6" value="187"/>
                <count group_id="O7" value="187"/>
                <count group_id="O8" value="174"/>
                <count group_id="O9" value="180"/>
                <count group_id="O10" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="68"/>
                    <measurement group_id="O5" value="60"/>
                    <measurement group_id="O6" value="77"/>
                    <measurement group_id="O7" value="60"/>
                    <measurement group_id="O8" value="67"/>
                    <measurement group_id="O9" value="42"/>
                    <measurement group_id="O10" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="74"/>
                    <measurement group_id="O7" value="37"/>
                    <measurement group_id="O8" value="49"/>
                    <measurement group_id="O9" value="23"/>
                    <measurement group_id="O10" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="32"/>
                    <measurement group_id="O7" value="19"/>
                    <measurement group_id="O8" value="20"/>
                    <measurement group_id="O9" value="17"/>
                    <measurement group_id="O10" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Seroconversion Factors at Day 21</title>
        <description>Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
        <time_frame>At Day 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody Seroconversion Factors at Day 21</title>
          <description>Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="189"/>
                <count group_id="O4" value="194"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="193"/>
                <count group_id="O7" value="192"/>
                <count group_id="O8" value="189"/>
                <count group_id="O9" value="187"/>
                <count group_id="O10" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="6.5" upper_limit="9.2"/>
                    <measurement group_id="O2" value="9.4" lower_limit="7.8" upper_limit="11.3"/>
                    <measurement group_id="O3" value="9.8" lower_limit="8.3" upper_limit="11.5"/>
                    <measurement group_id="O4" value="8.6" lower_limit="7.2" upper_limit="10.4"/>
                    <measurement group_id="O5" value="9.4" lower_limit="8.0" upper_limit="11.1"/>
                    <measurement group_id="O6" value="11.6" lower_limit="9.7" upper_limit="13.9"/>
                    <measurement group_id="O7" value="7.7" lower_limit="6.5" upper_limit="9.2"/>
                    <measurement group_id="O8" value="10.8" lower_limit="9.0" upper_limit="13.0"/>
                    <measurement group_id="O9" value="5.6" lower_limit="4.7" upper_limit="6.8"/>
                    <measurement group_id="O10" value="12.8" lower_limit="10.0" upper_limit="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="3.9" upper_limit="5.4"/>
                    <measurement group_id="O2" value="6.8" lower_limit="5.6" upper_limit="8.1"/>
                    <measurement group_id="O3" value="7.9" lower_limit="6.6" upper_limit="9.5"/>
                    <measurement group_id="O4" value="4.7" lower_limit="4.0" upper_limit="5.5"/>
                    <measurement group_id="O5" value="5.4" lower_limit="4.6" upper_limit="6.3"/>
                    <measurement group_id="O6" value="7.8" lower_limit="6.5" upper_limit="9.5"/>
                    <measurement group_id="O7" value="4.8" lower_limit="4.1" upper_limit="5.7"/>
                    <measurement group_id="O8" value="6.0" lower_limit="5.1" upper_limit="7.1"/>
                    <measurement group_id="O9" value="3.1" lower_limit="2.6" upper_limit="3.6"/>
                    <measurement group_id="O10" value="7.9" lower_limit="6.4" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="2.2" upper_limit="2.8"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.6" upper_limit="3.5"/>
                    <measurement group_id="O3" value="3.0" lower_limit="2.6" upper_limit="3.5"/>
                    <measurement group_id="O4" value="2.4" lower_limit="2.2" upper_limit="2.8"/>
                    <measurement group_id="O5" value="2.3" lower_limit="2.1" upper_limit="2.6"/>
                    <measurement group_id="O6" value="3.2" lower_limit="2.8" upper_limit="3.7"/>
                    <measurement group_id="O7" value="2.7" lower_limit="2.3" upper_limit="3.1"/>
                    <measurement group_id="O8" value="2.8" lower_limit="2.4" upper_limit="3.2"/>
                    <measurement group_id="O9" value="2.3" lower_limit="2.0" upper_limit="2.6"/>
                    <measurement group_id="O10" value="12.0" lower_limit="9.7" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Seroconversion Factors at Day 180</title>
        <description>Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
        <time_frame>At Day 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 180.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody Seroconversion Factors at Day 180</title>
          <description>Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 180.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="186"/>
                <count group_id="O3" value="180"/>
                <count group_id="O4" value="184"/>
                <count group_id="O5" value="180"/>
                <count group_id="O6" value="187"/>
                <count group_id="O7" value="187"/>
                <count group_id="O8" value="174"/>
                <count group_id="O9" value="180"/>
                <count group_id="O10" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.5" upper_limit="3.4"/>
                    <measurement group_id="O2" value="3.3" lower_limit="2.8" upper_limit="3.9"/>
                    <measurement group_id="O3" value="3.5" lower_limit="3.1" upper_limit="4.1"/>
                    <measurement group_id="O4" value="3.0" lower_limit="2.6" upper_limit="3.5"/>
                    <measurement group_id="O5" value="3.3" lower_limit="2.9" upper_limit="3.8"/>
                    <measurement group_id="O6" value="3.5" lower_limit="2.9" upper_limit="4.1"/>
                    <measurement group_id="O7" value="2.9" lower_limit="2.5" upper_limit="3.3"/>
                    <measurement group_id="O8" value="3.8" lower_limit="3.2" upper_limit="4.4"/>
                    <measurement group_id="O9" value="2.2" lower_limit="1.9" upper_limit="2.6"/>
                    <measurement group_id="O10" value="5.7" lower_limit="4.5" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.9" upper_limit="2.6"/>
                    <measurement group_id="O2" value="2.7" lower_limit="2.3" upper_limit="3.1"/>
                    <measurement group_id="O3" value="2.9" lower_limit="2.5" upper_limit="3.3"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.8" upper_limit="2.3"/>
                    <measurement group_id="O5" value="2.4" lower_limit="2.1" upper_limit="2.7"/>
                    <measurement group_id="O6" value="3.1" lower_limit="2.7" upper_limit="3.6"/>
                    <measurement group_id="O7" value="2.1" lower_limit="1.8" upper_limit="2.4"/>
                    <measurement group_id="O8" value="2.5" lower_limit="2.2" upper_limit="2.9"/>
                    <measurement group_id="O9" value="1.6" lower_limit="1.4" upper_limit="1.8"/>
                    <measurement group_id="O10" value="4.0" lower_limit="3.2" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.5" upper_limit="1.9"/>
                    <measurement group_id="O2" value="1.7" lower_limit="1.5" upper_limit="1.9"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.5" upper_limit="1.9"/>
                    <measurement group_id="O4" value="1.4" lower_limit="1.3" upper_limit="1.6"/>
                    <measurement group_id="O5" value="1.4" lower_limit="1.3" upper_limit="1.6"/>
                    <measurement group_id="O6" value="1.8" lower_limit="1.6" upper_limit="2.0"/>
                    <measurement group_id="O7" value="1.5" lower_limit="1.4" upper_limit="1.7"/>
                    <measurement group_id="O8" value="1.6" lower_limit="1.4" upper_limit="1.8"/>
                    <measurement group_id="O9" value="1.5" lower_limit="1.3" upper_limit="1.7"/>
                    <measurement group_id="O10" value="5.6" lower_limit="4.5" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21</title>
        <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
        <time_frame>At Day 0 and 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21</title>
          <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="192"/>
                <count group_id="O3" value="189"/>
                <count group_id="O4" value="194"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="193"/>
                <count group_id="O7" value="192"/>
                <count group_id="O8" value="189"/>
                <count group_id="O9" value="188"/>
                <count group_id="O10" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="44"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="26"/>
                    <measurement group_id="O9" value="31"/>
                    <measurement group_id="O10" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="168"/>
                    <measurement group_id="O3" value="171"/>
                    <measurement group_id="O4" value="158"/>
                    <measurement group_id="O5" value="169"/>
                    <measurement group_id="O6" value="172"/>
                    <measurement group_id="O7" value="153"/>
                    <measurement group_id="O8" value="163"/>
                    <measurement group_id="O9" value="132"/>
                    <measurement group_id="O10" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="124"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="139"/>
                    <measurement group_id="O5" value="131"/>
                    <measurement group_id="O6" value="139"/>
                    <measurement group_id="O7" value="130"/>
                    <measurement group_id="O8" value="134"/>
                    <measurement group_id="O9" value="132"/>
                    <measurement group_id="O10" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="189"/>
                    <measurement group_id="O3" value="188"/>
                    <measurement group_id="O4" value="190"/>
                    <measurement group_id="O5" value="192"/>
                    <measurement group_id="O6" value="191"/>
                    <measurement group_id="O7" value="187"/>
                    <measurement group_id="O8" value="185"/>
                    <measurement group_id="O9" value="179"/>
                    <measurement group_id="O10" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="140"/>
                    <measurement group_id="O3" value="138"/>
                    <measurement group_id="O4" value="148"/>
                    <measurement group_id="O5" value="156"/>
                    <measurement group_id="O6" value="149"/>
                    <measurement group_id="O7" value="139"/>
                    <measurement group_id="O8" value="145"/>
                    <measurement group_id="O9" value="144"/>
                    <measurement group_id="O10" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="183"/>
                    <measurement group_id="O3" value="184"/>
                    <measurement group_id="O4" value="187"/>
                    <measurement group_id="O5" value="186"/>
                    <measurement group_id="O6" value="192"/>
                    <measurement group_id="O7" value="182"/>
                    <measurement group_id="O8" value="184"/>
                    <measurement group_id="O9" value="183"/>
                    <measurement group_id="O10" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroprotected to HI Antibodies at Day 180</title>
        <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
        <time_frame>At Day 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 180.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroprotected to HI Antibodies at Day 180</title>
          <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 180.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="186"/>
                <count group_id="O3" value="180"/>
                <count group_id="O4" value="184"/>
                <count group_id="O5" value="180"/>
                <count group_id="O6" value="187"/>
                <count group_id="O7" value="187"/>
                <count group_id="O8" value="174"/>
                <count group_id="O9" value="181"/>
                <count group_id="O10" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="105"/>
                    <measurement group_id="O5" value="103"/>
                    <measurement group_id="O6" value="104"/>
                    <measurement group_id="O7" value="100"/>
                    <measurement group_id="O8" value="100"/>
                    <measurement group_id="O9" value="77"/>
                    <measurement group_id="O10" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172"/>
                    <measurement group_id="O2" value="170"/>
                    <measurement group_id="O3" value="162"/>
                    <measurement group_id="O4" value="164"/>
                    <measurement group_id="O5" value="170"/>
                    <measurement group_id="O6" value="179"/>
                    <measurement group_id="O7" value="166"/>
                    <measurement group_id="O8" value="160"/>
                    <measurement group_id="O9" value="156"/>
                    <measurement group_id="O10" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="166"/>
                    <measurement group_id="O3" value="168"/>
                    <measurement group_id="O4" value="168"/>
                    <measurement group_id="O5" value="166"/>
                    <measurement group_id="O6" value="176"/>
                    <measurement group_id="O7" value="158"/>
                    <measurement group_id="O8" value="162"/>
                    <measurement group_id="O9" value="162"/>
                    <measurement group_id="O10" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21</title>
        <description>The markers assessed were Cluster of Differentiation 4-All doubles i.e. CD4-All doubles, CD4-CD40Ligand(L), CD4-interferon gamma (CD4-IFNγ), CD4-interleukin 2 (CD4-IL2) and CD4-tumor necrosis factor alpha (CD4-TNFα). The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity cell mediated immunity (CMI) which included subjects for whom data concerning immunogenicity CMI outcome measures were available at day 21.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21</title>
          <description>The markers assessed were Cluster of Differentiation 4-All doubles i.e. CD4-All doubles, CD4-CD40Ligand(L), CD4-interferon gamma (CD4-IFNγ), CD4-interleukin 2 (CD4-IL2) and CD4-tumor necrosis factor alpha (CD4-TNFα). The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity cell mediated immunity (CMI) which included subjects for whom data concerning immunogenicity CMI outcome measures were available at day 21.</population>
          <units>cells per million CD4 T-cells</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="23"/>
                <count group_id="O9" value="23"/>
                <count group_id="O10" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands [CD4-All doubles] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.48" spread="278.18"/>
                    <measurement group_id="O2" value="283.18" spread="319.74"/>
                    <measurement group_id="O3" value="204.49" spread="236.05"/>
                    <measurement group_id="O4" value="200.21" spread="480.41"/>
                    <measurement group_id="O5" value="193.35" spread="324.34"/>
                    <measurement group_id="O6" value="177.44" spread="297.52"/>
                    <measurement group_id="O7" value="199.80" spread="310.58"/>
                    <measurement group_id="O8" value="222.58" spread="282.91"/>
                    <measurement group_id="O9" value="156.21" spread="518.89"/>
                    <measurement group_id="O10" value="538.72" spread="442.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD4-All doubles] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="441.16" spread="517.73"/>
                    <measurement group_id="O2" value="856.00" spread="685.35"/>
                    <measurement group_id="O3" value="704.14" spread="778.07"/>
                    <measurement group_id="O4" value="494.63" spread="883.53"/>
                    <measurement group_id="O5" value="483.24" spread="481.37"/>
                    <measurement group_id="O6" value="808.90" spread="858.38"/>
                    <measurement group_id="O7" value="655.32" spread="616.75"/>
                    <measurement group_id="O8" value="797.68" spread="5271.86"/>
                    <measurement group_id="O9" value="536.24" spread="578.48"/>
                    <measurement group_id="O10" value="1027.23" spread="838.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD4-All doubles] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="583.77" spread="563.98"/>
                    <measurement group_id="O2" value="488.70" spread="540.66"/>
                    <measurement group_id="O3" value="584.25" spread="626.26"/>
                    <measurement group_id="O4" value="309.67" spread="517.11"/>
                    <measurement group_id="O5" value="538.87" spread="691.59"/>
                    <measurement group_id="O6" value="702.79" spread="3741.48"/>
                    <measurement group_id="O7" value="457.98" spread="321.69"/>
                    <measurement group_id="O8" value="594.26" spread="598.83"/>
                    <measurement group_id="O9" value="427.71" spread="745.78"/>
                    <measurement group_id="O10" value="821.78" spread="646.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD4-All doubles] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1016.63" spread="990.97"/>
                    <measurement group_id="O2" value="1491.86" spread="899.50"/>
                    <measurement group_id="O3" value="1140.56" spread="955.61"/>
                    <measurement group_id="O4" value="1015.18" spread="1044.87"/>
                    <measurement group_id="O5" value="1051.06" spread="1024.97"/>
                    <measurement group_id="O6" value="1998.33" spread="2730.32"/>
                    <measurement group_id="O7" value="1234.37" spread="830.47"/>
                    <measurement group_id="O8" value="1302.34" spread="3490.03"/>
                    <measurement group_id="O9" value="922.62" spread="1170.30"/>
                    <measurement group_id="O10" value="1455.68" spread="870.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD4-All doubles] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="407.18" spread="456.82"/>
                    <measurement group_id="O2" value="596.53" spread="400.24"/>
                    <measurement group_id="O3" value="500.81" spread="734.64"/>
                    <measurement group_id="O4" value="250.48" spread="375.23"/>
                    <measurement group_id="O5" value="490.56" spread="546.12"/>
                    <measurement group_id="O6" value="259.15" spread="278.35"/>
                    <measurement group_id="O7" value="403.06" spread="482.16"/>
                    <measurement group_id="O8" value="442.39" spread="315.27"/>
                    <measurement group_id="O9" value="301.23" spread="584.68"/>
                    <measurement group_id="O10" value="1098.75" spread="909.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD4-All doubles] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1025.01" spread="736.55"/>
                    <measurement group_id="O2" value="1614.14" spread="953.74"/>
                    <measurement group_id="O3" value="1005.72" spread="1314.69"/>
                    <measurement group_id="O4" value="817.57" spread="675.70"/>
                    <measurement group_id="O5" value="1019.48" spread="698.91"/>
                    <measurement group_id="O6" value="1255.53" spread="941.27"/>
                    <measurement group_id="O7" value="1153.76" spread="699.26"/>
                    <measurement group_id="O8" value="1057.60" spread="4968.52"/>
                    <measurement group_id="O9" value="781.66" spread="880.46"/>
                    <measurement group_id="O10" value="1707.62" spread="1591.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD4-CD40L] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.19" spread="277.14"/>
                    <measurement group_id="O2" value="285.19" spread="319.80"/>
                    <measurement group_id="O3" value="193.56" spread="236.01"/>
                    <measurement group_id="O4" value="141.26" spread="500.24"/>
                    <measurement group_id="O5" value="192.02" spread="314.38"/>
                    <measurement group_id="O6" value="167.87" spread="296.47"/>
                    <measurement group_id="O7" value="153.91" spread="311.96"/>
                    <measurement group_id="O8" value="165.48" spread="281.57"/>
                    <measurement group_id="O9" value="150.60" spread="512.37"/>
                    <measurement group_id="O10" value="504.55" spread="441.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD4-CD40L] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418.24" spread="523.39"/>
                    <measurement group_id="O2" value="657.41" spread="684.48"/>
                    <measurement group_id="O3" value="641.98" spread="752.95"/>
                    <measurement group_id="O4" value="471.56" spread="881.73"/>
                    <measurement group_id="O5" value="391.29" spread="474.16"/>
                    <measurement group_id="O6" value="510.16" spread="871.38"/>
                    <measurement group_id="O7" value="599.32" spread="592.08"/>
                    <measurement group_id="O8" value="697.39" spread="5282.26"/>
                    <measurement group_id="O9" value="406.14" spread="571.70"/>
                    <measurement group_id="O10" value="967.83" spread="848.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD4-CD40L] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="555.20" spread="555.43"/>
                    <measurement group_id="O2" value="477.12" spread="531.36"/>
                    <measurement group_id="O3" value="527.80" spread="613.23"/>
                    <measurement group_id="O4" value="284.63" spread="522.58"/>
                    <measurement group_id="O5" value="511.21" spread="679.89"/>
                    <measurement group_id="O6" value="587.17" spread="1872.24"/>
                    <measurement group_id="O7" value="418.98" spread="333.83"/>
                    <measurement group_id="O8" value="568.96" spread="559.46"/>
                    <measurement group_id="O9" value="322.37" spread="713.98"/>
                    <measurement group_id="O10" value="742.80" spread="659.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD4-CD40L] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="941.04" spread="994.45"/>
                    <measurement group_id="O2" value="1438.93" spread="881.80"/>
                    <measurement group_id="O3" value="1014.97" spread="933.09"/>
                    <measurement group_id="O4" value="940.53" spread="1065.84"/>
                    <measurement group_id="O5" value="977.44" spread="970.75"/>
                    <measurement group_id="O6" value="1763.75" spread="1858.49"/>
                    <measurement group_id="O7" value="1162.09" spread="715.63"/>
                    <measurement group_id="O8" value="1156.07" spread="3501.25"/>
                    <measurement group_id="O9" value="798.75" spread="1155.23"/>
                    <measurement group_id="O10" value="1383.25" spread="871.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD4-CD40L] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="387.03" spread="429.86"/>
                    <measurement group_id="O2" value="587.72" spread="396.47"/>
                    <measurement group_id="O3" value="446.80" spread="736.88"/>
                    <measurement group_id="O4" value="219.83" spread="386.13"/>
                    <measurement group_id="O5" value="479.21" spread="550.01"/>
                    <measurement group_id="O6" value="256.73" spread="280.28"/>
                    <measurement group_id="O7" value="383.93" spread="466.87"/>
                    <measurement group_id="O8" value="431.32" spread="319.06"/>
                    <measurement group_id="O9" value="342.65" spread="589.08"/>
                    <measurement group_id="O10" value="1076.46" spread="903.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD4-CD40L] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="926.13" spread="749.19"/>
                    <measurement group_id="O2" value="1570.30" spread="962.36"/>
                    <measurement group_id="O3" value="958.63" spread="1315.41"/>
                    <measurement group_id="O4" value="754.45" spread="694.91"/>
                    <measurement group_id="O5" value="975.92" spread="710.25"/>
                    <measurement group_id="O6" value="1160.31" spread="959.34"/>
                    <measurement group_id="O7" value="1039.13" spread="699.33"/>
                    <measurement group_id="O8" value="957.22" spread="5023.06"/>
                    <measurement group_id="O9" value="707.72" spread="874.64"/>
                    <measurement group_id="O10" value="1614.08" spread="1617.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD4-IFNγ] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.65" spread="195.65"/>
                    <measurement group_id="O2" value="190.19" spread="245.89"/>
                    <measurement group_id="O3" value="158.04" spread="192.23"/>
                    <measurement group_id="O4" value="235.01" spread="355.44"/>
                    <measurement group_id="O5" value="171.07" spread="194.84"/>
                    <measurement group_id="O6" value="137.02" spread="189.76"/>
                    <measurement group_id="O7" value="203.95" spread="254.48"/>
                    <measurement group_id="O8" value="184.52" spread="211.26"/>
                    <measurement group_id="O9" value="198.86" spread="422.78"/>
                    <measurement group_id="O10" value="380.34" spread="384.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD4-IFNγ] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398.57" spread="370.41"/>
                    <measurement group_id="O2" value="636.42" spread="570.57"/>
                    <measurement group_id="O3" value="532.84" spread="488.63"/>
                    <measurement group_id="O4" value="426.15" spread="660.07"/>
                    <measurement group_id="O5" value="379.49" spread="361.80"/>
                    <measurement group_id="O6" value="543.09" spread="681.65"/>
                    <measurement group_id="O7" value="467.66" spread="450.93"/>
                    <measurement group_id="O8" value="576.14" spread="4664.15"/>
                    <measurement group_id="O9" value="442.66" spread="449.36"/>
                    <measurement group_id="O10" value="755.12" spread="645.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD4-IFNγ] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361.99" spread="378.72"/>
                    <measurement group_id="O2" value="350.04" spread="325.28"/>
                    <measurement group_id="O3" value="332.39" spread="326.71"/>
                    <measurement group_id="O4" value="295.56" spread="424.20"/>
                    <measurement group_id="O5" value="243.93" spread="321.57"/>
                    <measurement group_id="O6" value="495.18" spread="3550.69"/>
                    <measurement group_id="O7" value="305.13" spread="248.40"/>
                    <measurement group_id="O8" value="310.45" spread="276.10"/>
                    <measurement group_id="O9" value="272.34" spread="453.35"/>
                    <measurement group_id="O10" value="589.57" spread="493.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD4-IFNγ] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="644.07" spread="707.63"/>
                    <measurement group_id="O2" value="891.98" spread="719.87"/>
                    <measurement group_id="O3" value="809.46" spread="590.21"/>
                    <measurement group_id="O4" value="606.43" spread="745.80"/>
                    <measurement group_id="O5" value="651.21" spread="651.51"/>
                    <measurement group_id="O6" value="1293.10" spread="2390.91"/>
                    <measurement group_id="O7" value="718.87" spread="619.16"/>
                    <measurement group_id="O8" value="691.57" spread="2944.57"/>
                    <measurement group_id="O9" value="548.91" spread="732.46"/>
                    <measurement group_id="O10" value="976.96" spread="643.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD4-IFNγ] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336.70" spread="352.20"/>
                    <measurement group_id="O2" value="403.08" spread="319.99"/>
                    <measurement group_id="O3" value="322.07" spread="631.98"/>
                    <measurement group_id="O4" value="302.23" spread="249.59"/>
                    <measurement group_id="O5" value="248.66" spread="236.24"/>
                    <measurement group_id="O6" value="237.57" spread="200.43"/>
                    <measurement group_id="O7" value="277.94" spread="372.05"/>
                    <measurement group_id="O8" value="210.23" spread="266.19"/>
                    <measurement group_id="O9" value="256.03" spread="440.55"/>
                    <measurement group_id="O10" value="874.82" spread="729.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD4-IFNγ] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="716.86" spread="601.16"/>
                    <measurement group_id="O2" value="1163.80" spread="865.47"/>
                    <measurement group_id="O3" value="855.95" spread="1073.89"/>
                    <measurement group_id="O4" value="509.84" spread="520.06"/>
                    <measurement group_id="O5" value="611.65" spread="527.80"/>
                    <measurement group_id="O6" value="852.80" spread="715.28"/>
                    <measurement group_id="O7" value="745.46" spread="575.21"/>
                    <measurement group_id="O8" value="709.84" spread="4385.83"/>
                    <measurement group_id="O9" value="523.15" spread="697.47"/>
                    <measurement group_id="O10" value="1306.18" spread="1346.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD4-IL2] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.54" spread="242.60"/>
                    <measurement group_id="O2" value="193.42" spread="297.22"/>
                    <measurement group_id="O3" value="188.29" spread="215.39"/>
                    <measurement group_id="O4" value="150.59" spread="407.63"/>
                    <measurement group_id="O5" value="152.22" spread="284.11"/>
                    <measurement group_id="O6" value="157.54" spread="255.06"/>
                    <measurement group_id="O7" value="161.81" spread="293.16"/>
                    <measurement group_id="O8" value="170.79" spread="253.02"/>
                    <measurement group_id="O9" value="122.12" spread="451.59"/>
                    <measurement group_id="O10" value="356.84" spread="313.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD4-IL2] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299.14" spread="421.84"/>
                    <measurement group_id="O2" value="664.46" spread="582.79"/>
                    <measurement group_id="O3" value="559.98" spread="642.32"/>
                    <measurement group_id="O4" value="415.13" spread="691.39"/>
                    <measurement group_id="O5" value="409.73" spread="365.35"/>
                    <measurement group_id="O6" value="677.81" spread="689.59"/>
                    <measurement group_id="O7" value="529.19" spread="520.65"/>
                    <measurement group_id="O8" value="678.22" spread="4760.15"/>
                    <measurement group_id="O9" value="461.05" spread="498.00"/>
                    <measurement group_id="O10" value="813.73" spread="693.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD4-IL2] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406.48" spread="508.99"/>
                    <measurement group_id="O2" value="382.61" spread="428.51"/>
                    <measurement group_id="O3" value="516.80" spread="421.85"/>
                    <measurement group_id="O4" value="251.35" spread="445.04"/>
                    <measurement group_id="O5" value="388.89" spread="560.47"/>
                    <measurement group_id="O6" value="532.86" spread="708.29"/>
                    <measurement group_id="O7" value="393.79" spread="295.93"/>
                    <measurement group_id="O8" value="470.64" spread="443.13"/>
                    <measurement group_id="O9" value="343.41" spread="607.93"/>
                    <measurement group_id="O10" value="589.89" spread="469.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD4-IL2] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="747.93" spread="778.49"/>
                    <measurement group_id="O2" value="1082.78" spread="712.53"/>
                    <measurement group_id="O3" value="1010.24" spread="772.39"/>
                    <measurement group_id="O4" value="762.07" spread="766.05"/>
                    <measurement group_id="O5" value="792.75" spread="828.41"/>
                    <measurement group_id="O6" value="1425.03" spread="1236.35"/>
                    <measurement group_id="O7" value="908.72" spread="680.48"/>
                    <measurement group_id="O8" value="1041.76" spread="2883.12"/>
                    <measurement group_id="O9" value="733.36" spread="900.95"/>
                    <measurement group_id="O10" value="1061.62" spread="635.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD4-IL2] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277.98" spread="394.46"/>
                    <measurement group_id="O2" value="491.65" spread="369.85"/>
                    <measurement group_id="O3" value="434.78" spread="621.10"/>
                    <measurement group_id="O4" value="190.27" spread="322.46"/>
                    <measurement group_id="O5" value="411.11" spread="457.99"/>
                    <measurement group_id="O6" value="269.03" spread="243.51"/>
                    <measurement group_id="O7" value="360.78" spread="420.71"/>
                    <measurement group_id="O8" value="333.95" spread="309.81"/>
                    <measurement group_id="O9" value="221.19" spread="537.35"/>
                    <measurement group_id="O10" value="871.60" spread="724.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD4-IL2] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="791.31" spread="616.06"/>
                    <measurement group_id="O2" value="1295.22" spread="856.91"/>
                    <measurement group_id="O3" value="992.50" spread="1134.21"/>
                    <measurement group_id="O4" value="692.82" spread="570.55"/>
                    <measurement group_id="O5" value="876.95" spread="569.97"/>
                    <measurement group_id="O6" value="1038.01" spread="765.73"/>
                    <measurement group_id="O7" value="949.33" spread="588.11"/>
                    <measurement group_id="O8" value="872.00" spread="4655.93"/>
                    <measurement group_id="O9" value="695.83" spread="757.57"/>
                    <measurement group_id="O10" value="1348.21" spread="1359.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD4-TNFα] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.32" spread="201.60"/>
                    <measurement group_id="O2" value="155.22" spread="184.44"/>
                    <measurement group_id="O3" value="130.19" spread="152.33"/>
                    <measurement group_id="O4" value="124.70" spread="306.20"/>
                    <measurement group_id="O5" value="143.44" spread="199.20"/>
                    <measurement group_id="O6" value="112.41" spread="169.39"/>
                    <measurement group_id="O7" value="100.38" spread="185.42"/>
                    <measurement group_id="O8" value="111.07" spread="179.39"/>
                    <measurement group_id="O9" value="104.10" spread="311.25"/>
                    <measurement group_id="O10" value="234.98" spread="234.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD4-TNFα] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234.99" spread="298.31"/>
                    <measurement group_id="O2" value="440.26" spread="451.77"/>
                    <measurement group_id="O3" value="333.95" spread="487.76"/>
                    <measurement group_id="O4" value="279.64" spread="553.81"/>
                    <measurement group_id="O5" value="296.79" spread="289.33"/>
                    <measurement group_id="O6" value="336.45" spread="541.95"/>
                    <measurement group_id="O7" value="325.65" spread="410.44"/>
                    <measurement group_id="O8" value="449.86" spread="3979.03"/>
                    <measurement group_id="O9" value="273.66" spread="355.95"/>
                    <measurement group_id="O10" value="490.23" spread="532.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD4-TNFα] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351.26" spread="450.82"/>
                    <measurement group_id="O2" value="458.02" spread="373.43"/>
                    <measurement group_id="O3" value="432.24" spread="487.63"/>
                    <measurement group_id="O4" value="342.30" spread="455.39"/>
                    <measurement group_id="O5" value="404.64" spread="410.30"/>
                    <measurement group_id="O6" value="600.83" spread="3581.08"/>
                    <measurement group_id="O7" value="303.13" spread="263.25"/>
                    <measurement group_id="O8" value="420.75" spread="422.38"/>
                    <measurement group_id="O9" value="327.09" spread="552.26"/>
                    <measurement group_id="O10" value="667.60" spread="450.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD4-TNFα] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="712.96" spread="700.26"/>
                    <measurement group_id="O2" value="944.29" spread="589.91"/>
                    <measurement group_id="O3" value="852.44" spread="637.30"/>
                    <measurement group_id="O4" value="623.21" spread="728.42"/>
                    <measurement group_id="O5" value="702.41" spread="635.67"/>
                    <measurement group_id="O6" value="1293.59" spread="2431.45"/>
                    <measurement group_id="O7" value="802.15" spread="591.12"/>
                    <measurement group_id="O8" value="884.71" spread="2654.95"/>
                    <measurement group_id="O9" value="575.97" spread="723.76"/>
                    <measurement group_id="O10" value="995.86" spread="630.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD4-TNFα] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203.89" spread="281.14"/>
                    <measurement group_id="O2" value="239.73" spread="260.28"/>
                    <measurement group_id="O3" value="225.66" spread="501.91"/>
                    <measurement group_id="O4" value="118.04" spread="257.63"/>
                    <measurement group_id="O5" value="241.23" spread="332.43"/>
                    <measurement group_id="O6" value="117.51" spread="175.00"/>
                    <measurement group_id="O7" value="152.19" spread="297.33"/>
                    <measurement group_id="O8" value="193.88" spread="141.46"/>
                    <measurement group_id="O9" value="126.64" spread="402.92"/>
                    <measurement group_id="O10" value="605.04" spread="641.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD4-TNFα] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="509.26" spread="451.20"/>
                    <measurement group_id="O2" value="806.86" spread="561.77"/>
                    <measurement group_id="O3" value="601.64" spread="763.90"/>
                    <measurement group_id="O4" value="312.72" spread="391.89"/>
                    <measurement group_id="O5" value="518.35" spread="419.60"/>
                    <measurement group_id="O6" value="580.98" spread="579.68"/>
                    <measurement group_id="O7" value="547.64" spread="464.44"/>
                    <measurement group_id="O8" value="540.54" spread="3022.19"/>
                    <measurement group_id="O9" value="285.50" spread="526.85"/>
                    <measurement group_id="O10" value="805.41" spread="1133.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180</title>
        <description>The markers assessed were CD4-All doubles, CD4-CD40L, CD4-IFNγ, CD4-IL2 and CD4-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
        <time_frame>At Day 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence for cell mediated immunity (CMI) which included subjects for whom data concerning immunogenicity CMI outcome measures were available at day 180.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180</title>
          <description>The markers assessed were CD4-All doubles, CD4-CD40L, CD4-IFNγ, CD4-IL2 and CD4-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence for cell mediated immunity (CMI) which included subjects for whom data concerning immunogenicity CMI outcome measures were available at day 180.</population>
          <units>cells per million CD4 T-cells</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="19"/>
                <count group_id="O8" value="16"/>
                <count group_id="O9" value="16"/>
                <count group_id="O10" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands [CD4-All doubles]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393.50" spread="359.42"/>
                    <measurement group_id="O2" value="348.12" spread="422.44"/>
                    <measurement group_id="O3" value="666.01" spread="663.86"/>
                    <measurement group_id="O4" value="394.45" spread="508.40"/>
                    <measurement group_id="O5" value="432.70" spread="374.70"/>
                    <measurement group_id="O6" value="421.08" spread="613.81"/>
                    <measurement group_id="O7" value="357.66" spread="470.53"/>
                    <measurement group_id="O8" value="224.47" spread="332.47"/>
                    <measurement group_id="O9" value="714.85" spread="658.37"/>
                    <measurement group_id="O10" value="1070.14" spread="874.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD4-All doubles]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="802.04" spread="391.96"/>
                    <measurement group_id="O2" value="603.15" spread="559.07"/>
                    <measurement group_id="O3" value="720.91" spread="829.77"/>
                    <measurement group_id="O4" value="463.85" spread="832.67"/>
                    <measurement group_id="O5" value="728.09" spread="640.63"/>
                    <measurement group_id="O6" value="676.69" spread="785.39"/>
                    <measurement group_id="O7" value="670.60" spread="881.04"/>
                    <measurement group_id="O8" value="566.79" spread="522.16"/>
                    <measurement group_id="O9" value="638.11" spread="929.43"/>
                    <measurement group_id="O10" value="1366.02" spread="966.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD4-All doubles]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="679.05" spread="4150.67"/>
                    <measurement group_id="O2" value="807.74" spread="629.48"/>
                    <measurement group_id="O3" value="807.96" spread="901.44"/>
                    <measurement group_id="O4" value="416.48" spread="442.15"/>
                    <measurement group_id="O5" value="774.07" spread="452.40"/>
                    <measurement group_id="O6" value="423.03" spread="839.74"/>
                    <measurement group_id="O7" value="582.68" spread="429.62"/>
                    <measurement group_id="O8" value="588.22" spread="334.48"/>
                    <measurement group_id="O9" value="742.01" spread="481.80"/>
                    <measurement group_id="O10" value="1304.54" spread="1096.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD4-CD40L]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="348.06" spread="342.53"/>
                    <measurement group_id="O2" value="319.80" spread="403.11"/>
                    <measurement group_id="O3" value="622.84" spread="626.39"/>
                    <measurement group_id="O4" value="361.05" spread="490.66"/>
                    <measurement group_id="O5" value="425.72" spread="346.49"/>
                    <measurement group_id="O6" value="471.70" spread="566.40"/>
                    <measurement group_id="O7" value="353.82" spread="432.84"/>
                    <measurement group_id="O8" value="234.90" spread="304.83"/>
                    <measurement group_id="O9" value="690.69" spread="642.61"/>
                    <measurement group_id="O10" value="999.02" spread="831.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD4-CD40L]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="733.96" spread="397.17"/>
                    <measurement group_id="O2" value="576.04" spread="543.29"/>
                    <measurement group_id="O3" value="682.43" spread="823.68"/>
                    <measurement group_id="O4" value="439.97" spread="825.94"/>
                    <measurement group_id="O5" value="680.00" spread="607.45"/>
                    <measurement group_id="O6" value="683.28" spread="761.14"/>
                    <measurement group_id="O7" value="623.11" spread="800.89"/>
                    <measurement group_id="O8" value="554.83" spread="502.42"/>
                    <measurement group_id="O9" value="625.97" spread="924.73"/>
                    <measurement group_id="O10" value="1268.21" spread="889.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD4-CD40L]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="621.50" spread="3427.50"/>
                    <measurement group_id="O2" value="764.21" spread="613.38"/>
                    <measurement group_id="O3" value="779.35" spread="887.41"/>
                    <measurement group_id="O4" value="394.05" spread="415.93"/>
                    <measurement group_id="O5" value="743.85" spread="425.01"/>
                    <measurement group_id="O6" value="414.76" spread="732.26"/>
                    <measurement group_id="O7" value="592.52" spread="424.79"/>
                    <measurement group_id="O8" value="537.41" spread="351.86"/>
                    <measurement group_id="O9" value="679.16" spread="486.34"/>
                    <measurement group_id="O10" value="1260.62" spread="1067.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD4-IFNγ]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244.53" spread="325.64"/>
                    <measurement group_id="O2" value="375.03" spread="308.38"/>
                    <measurement group_id="O3" value="392.18" spread="500.72"/>
                    <measurement group_id="O4" value="280.73" spread="402.63"/>
                    <measurement group_id="O5" value="261.43" spread="263.15"/>
                    <measurement group_id="O6" value="338.11" spread="488.06"/>
                    <measurement group_id="O7" value="271.38" spread="373.04"/>
                    <measurement group_id="O8" value="136.97" spread="262.56"/>
                    <measurement group_id="O9" value="445.44" spread="577.53"/>
                    <measurement group_id="O10" value="867.78" spread="658.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD4-IFNγ]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="492.75" spread="320.15"/>
                    <measurement group_id="O2" value="476.37" spread="416.85"/>
                    <measurement group_id="O3" value="548.14" spread="557.60"/>
                    <measurement group_id="O4" value="372.77" spread="618.70"/>
                    <measurement group_id="O5" value="399.91" spread="481.00"/>
                    <measurement group_id="O6" value="325.70" spread="547.57"/>
                    <measurement group_id="O7" value="523.69" spread="683.65"/>
                    <measurement group_id="O8" value="374.66" spread="407.51"/>
                    <measurement group_id="O9" value="467.74" spread="807.28"/>
                    <measurement group_id="O10" value="971.26" spread="783.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD4-IFNγ]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="522.75" spread="3348.47"/>
                    <measurement group_id="O2" value="510.43" spread="462.45"/>
                    <measurement group_id="O3" value="457.89" spread="774.10"/>
                    <measurement group_id="O4" value="253.06" spread="234.64"/>
                    <measurement group_id="O5" value="411.84" spread="384.77"/>
                    <measurement group_id="O6" value="240.48" spread="567.12"/>
                    <measurement group_id="O7" value="361.94" spread="357.95"/>
                    <measurement group_id="O8" value="360.90" spread="250.90"/>
                    <measurement group_id="O9" value="458.80" spread="456.80"/>
                    <measurement group_id="O10" value="1073.05" spread="935.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD4-IL2]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316.88" spread="297.00"/>
                    <measurement group_id="O2" value="314.96" spread="372.22"/>
                    <measurement group_id="O3" value="558.83" spread="549.83"/>
                    <measurement group_id="O4" value="304.00" spread="404.11"/>
                    <measurement group_id="O5" value="368.31" spread="348.92"/>
                    <measurement group_id="O6" value="400.05" spread="505.26"/>
                    <measurement group_id="O7" value="304.33" spread="467.47"/>
                    <measurement group_id="O8" value="175.36" spread="258.68"/>
                    <measurement group_id="O9" value="691.47" spread="597.60"/>
                    <measurement group_id="O10" value="859.06" spread="642.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD4-IL2]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="579.40" spread="330.85"/>
                    <measurement group_id="O2" value="426.54" spread="422.19"/>
                    <measurement group_id="O3" value="529.59" spread="677.44"/>
                    <measurement group_id="O4" value="480.46" spread="667.59"/>
                    <measurement group_id="O5" value="603.02" spread="608.61"/>
                    <measurement group_id="O6" value="551.29" spread="712.29"/>
                    <measurement group_id="O7" value="489.69" spread="841.98"/>
                    <measurement group_id="O8" value="339.94" spread="440.33"/>
                    <measurement group_id="O9" value="700.87" spread="861.25"/>
                    <measurement group_id="O10" value="1011.95" spread="565.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD4-IL2]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="549.00" spread="2767.21"/>
                    <measurement group_id="O2" value="617.40" spread="602.01"/>
                    <measurement group_id="O3" value="698.16" spread="823.21"/>
                    <measurement group_id="O4" value="315.90" spread="393.50"/>
                    <measurement group_id="O5" value="672.69" spread="432.34"/>
                    <measurement group_id="O6" value="373.28" spread="680.43"/>
                    <measurement group_id="O7" value="518.17" spread="374.93"/>
                    <measurement group_id="O8" value="345.05" spread="300.46"/>
                    <measurement group_id="O9" value="612.61" spread="455.63"/>
                    <measurement group_id="O10" value="1119.01" spread="801.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD4-TNFα]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280.19" spread="284.35"/>
                    <measurement group_id="O2" value="188.48" spread="325.58"/>
                    <measurement group_id="O3" value="382.50" spread="490.32"/>
                    <measurement group_id="O4" value="200.30" spread="422.18"/>
                    <measurement group_id="O5" value="263.40" spread="301.07"/>
                    <measurement group_id="O6" value="350.38" spread="473.03"/>
                    <measurement group_id="O7" value="254.19" spread="373.61"/>
                    <measurement group_id="O8" value="228.89" spread="247.41"/>
                    <measurement group_id="O9" value="533.13" spread="517.19"/>
                    <measurement group_id="O10" value="730.49" spread="549.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD4-TNFα]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="722.29" spread="288.16"/>
                    <measurement group_id="O2" value="600.27" spread="472.44"/>
                    <measurement group_id="O3" value="626.23" spread="655.14"/>
                    <measurement group_id="O4" value="395.86" spread="758.84"/>
                    <measurement group_id="O5" value="599.10" spread="496.66"/>
                    <measurement group_id="O6" value="512.38" spread="740.10"/>
                    <measurement group_id="O7" value="601.79" spread="703.08"/>
                    <measurement group_id="O8" value="561.14" spread="451.82"/>
                    <measurement group_id="O9" value="521.03" spread="873.58"/>
                    <measurement group_id="O10" value="1187.70" spread="734.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD4-TNFα]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="538.21" spread="2445.31"/>
                    <measurement group_id="O2" value="576.09" spread="352.91"/>
                    <measurement group_id="O3" value="408.52" spread="712.70"/>
                    <measurement group_id="O4" value="149.41" spread="359.72"/>
                    <measurement group_id="O5" value="476.90" spread="332.91"/>
                    <measurement group_id="O6" value="160.26" spread="542.67"/>
                    <measurement group_id="O7" value="360.57" spread="367.88"/>
                    <measurement group_id="O8" value="385.22" spread="227.19"/>
                    <measurement group_id="O9" value="505.39" spread="393.49"/>
                    <measurement group_id="O10" value="798.97" spread="716.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21</title>
        <description>The markers assessed were Cluster of Differentiation 8-All doubles i.e. CD8-All doubles, CD8-CD40L, CD8-IFNγ, CD8-IL2 and CD8-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity cell mediated immunity (CMI) which included subjects for whom data concerning immunogenicity CMI outcome measures were available at day 21.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21</title>
          <description>The markers assessed were Cluster of Differentiation 8-All doubles i.e. CD8-All doubles, CD8-CD40L, CD8-IFNγ, CD8-IL2 and CD8-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity cell mediated immunity (CMI) which included subjects for whom data concerning immunogenicity CMI outcome measures were available at day 21.</population>
          <units>cells per million CD8 T-cells</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="23"/>
                <count group_id="O9" value="23"/>
                <count group_id="O10" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands [CD8-All doubles] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.10" spread="135.40"/>
                    <measurement group_id="O2" value="12.90" spread="151.71"/>
                    <measurement group_id="O3" value="14.46" spread="122.65"/>
                    <measurement group_id="O4" value="3.25" spread="53.78"/>
                    <measurement group_id="O5" value="3.31" spread="91.60"/>
                    <measurement group_id="O6" value="2.31" spread="47.88"/>
                    <measurement group_id="O7" value="2.63" spread="98.13"/>
                    <measurement group_id="O8" value="6.83" spread="67.42"/>
                    <measurement group_id="O9" value="13.81" spread="116.94"/>
                    <measurement group_id="O10" value="7.69" spread="91.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD8-All doubles] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.45" spread="97.10"/>
                    <measurement group_id="O2" value="12.20" spread="127.89"/>
                    <measurement group_id="O3" value="9.54" spread="116.11"/>
                    <measurement group_id="O4" value="5.14" spread="87.63"/>
                    <measurement group_id="O5" value="4.87" spread="92.78"/>
                    <measurement group_id="O6" value="4.71" spread="49.37"/>
                    <measurement group_id="O7" value="9.62" spread="50.39"/>
                    <measurement group_id="O8" value="4.76" spread="132.76"/>
                    <measurement group_id="O9" value="6.33" spread="91.54"/>
                    <measurement group_id="O10" value="2.34" spread="132.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD8-All doubles] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.69" spread="178.06"/>
                    <measurement group_id="O2" value="6.81" spread="126.03"/>
                    <measurement group_id="O3" value="9.85" spread="344.91"/>
                    <measurement group_id="O4" value="3.93" spread="124.78"/>
                    <measurement group_id="O5" value="6.67" spread="112.61"/>
                    <measurement group_id="O6" value="5.53" spread="169.17"/>
                    <measurement group_id="O7" value="8.19" spread="95.91"/>
                    <measurement group_id="O8" value="6.73" spread="108.10"/>
                    <measurement group_id="O9" value="8.22" spread="153.57"/>
                    <measurement group_id="O10" value="9.16" spread="63.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD8-All doubles] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.08" spread="84.59"/>
                    <measurement group_id="O2" value="7.54" spread="234.23"/>
                    <measurement group_id="O3" value="9.77" spread="292.05"/>
                    <measurement group_id="O4" value="4.15" spread="66.82"/>
                    <measurement group_id="O5" value="7.73" spread="139.86"/>
                    <measurement group_id="O6" value="12.49" spread="189.06"/>
                    <measurement group_id="O7" value="16.86" spread="219.38"/>
                    <measurement group_id="O8" value="4.99" spread="168.28"/>
                    <measurement group_id="O9" value="39.03" spread="123.00"/>
                    <measurement group_id="O10" value="2.00" spread="57.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD8-All doubles] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.62" spread="200.31"/>
                    <measurement group_id="O2" value="15.68" spread="423.52"/>
                    <measurement group_id="O3" value="30.58" spread="282.37"/>
                    <measurement group_id="O4" value="10.85" spread="215.20"/>
                    <measurement group_id="O5" value="6.74" spread="63.87"/>
                    <measurement group_id="O6" value="2.48" spread="44.95"/>
                    <measurement group_id="O7" value="26.27" spread="218.28"/>
                    <measurement group_id="O8" value="23.57" spread="184.06"/>
                    <measurement group_id="O9" value="16.83" spread="232.88"/>
                    <measurement group_id="O10" value="11.02" spread="175.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD8-All doubles] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.50" spread="296.07"/>
                    <measurement group_id="O2" value="44.96" spread="351.05"/>
                    <measurement group_id="O3" value="20.54" spread="188.50"/>
                    <measurement group_id="O4" value="8.09" spread="302.34"/>
                    <measurement group_id="O5" value="31.02" spread="243.07"/>
                    <measurement group_id="O6" value="22.20" spread="183.56"/>
                    <measurement group_id="O7" value="60.96" spread="415.86"/>
                    <measurement group_id="O8" value="13.39" spread="193.75"/>
                    <measurement group_id="O9" value="24.91" spread="153.61"/>
                    <measurement group_id="O10" value="16.20" spread="225.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD8-CD40L] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.68" spread="76.49"/>
                    <measurement group_id="O2" value="9.18" spread="141.09"/>
                    <measurement group_id="O3" value="7.64" spread="81.73"/>
                    <measurement group_id="O4" value="2.31" spread="25.28"/>
                    <measurement group_id="O5" value="2.75" spread="106.31"/>
                    <measurement group_id="O6" value="1.47" spread="26.08"/>
                    <measurement group_id="O7" value="2.39" spread="55.56"/>
                    <measurement group_id="O8" value="2.94" spread="67.71"/>
                    <measurement group_id="O9" value="10.48" spread="95.48"/>
                    <measurement group_id="O10" value="2.70" spread="77.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD8-CD40L] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" spread="69.81"/>
                    <measurement group_id="O2" value="3.41" spread="98.02"/>
                    <measurement group_id="O3" value="8.71" spread="75.81"/>
                    <measurement group_id="O4" value="2.20" spread="47.58"/>
                    <measurement group_id="O5" value="3.22" spread="72.42"/>
                    <measurement group_id="O6" value="2.21" spread="42.86"/>
                    <measurement group_id="O7" value="3.36" spread="55.81"/>
                    <measurement group_id="O8" value="3.45" spread="82.08"/>
                    <measurement group_id="O9" value="2.30" spread="53.40"/>
                    <measurement group_id="O10" value="2.97" spread="43.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD8-CD40L] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="51.86"/>
                    <measurement group_id="O2" value="2.17" spread="41.97"/>
                    <measurement group_id="O3" value="5.20" spread="70.37"/>
                    <measurement group_id="O4" value="1.82" spread="70.40"/>
                    <measurement group_id="O5" value="2.78" spread="66.95"/>
                    <measurement group_id="O6" value="1.47" spread="26.82"/>
                    <measurement group_id="O7" value="3.10" spread="43.93"/>
                    <measurement group_id="O8" value="2.08" spread="53.94"/>
                    <measurement group_id="O9" value="4.55" spread="93.16"/>
                    <measurement group_id="O10" value="2.96" spread="99.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD8-CD40L] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" spread="45.67"/>
                    <measurement group_id="O2" value="5.72" spread="165.77"/>
                    <measurement group_id="O3" value="4.19" spread="52.99"/>
                    <measurement group_id="O4" value="3.00" spread="45.24"/>
                    <measurement group_id="O5" value="5.72" spread="90.85"/>
                    <measurement group_id="O6" value="5.01" spread="88.79"/>
                    <measurement group_id="O7" value="5.58" spread="98.17"/>
                    <measurement group_id="O8" value="5.17" spread="34.65"/>
                    <measurement group_id="O9" value="7.27" spread="43.58"/>
                    <measurement group_id="O10" value="2.04" spread="35.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD8-CD40L] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" spread="54.73"/>
                    <measurement group_id="O2" value="7.16" spread="290.97"/>
                    <measurement group_id="O3" value="6.53" spread="132.89"/>
                    <measurement group_id="O4" value="2.82" spread="87.95"/>
                    <measurement group_id="O5" value="2.84" spread="47.37"/>
                    <measurement group_id="O6" value="1.66" spread="34.20"/>
                    <measurement group_id="O7" value="3.29" spread="76.69"/>
                    <measurement group_id="O8" value="5.21" spread="59.00"/>
                    <measurement group_id="O9" value="5.52" spread="168.72"/>
                    <measurement group_id="O10" value="3.98" spread="95.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD8-CD40L] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" spread="127.60"/>
                    <measurement group_id="O2" value="12.06" spread="265.01"/>
                    <measurement group_id="O3" value="3.74" spread="115.89"/>
                    <measurement group_id="O4" value="4.45" spread="142.55"/>
                    <measurement group_id="O5" value="9.13" spread="183.09"/>
                    <measurement group_id="O6" value="5.64" spread="138.31"/>
                    <measurement group_id="O7" value="8.97" spread="271.08"/>
                    <measurement group_id="O8" value="4.47" spread="183.70"/>
                    <measurement group_id="O9" value="3.43" spread="72.64"/>
                    <measurement group_id="O10" value="9.50" spread="127.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD8-IFNγ] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.38" spread="115.60"/>
                    <measurement group_id="O2" value="8.63" spread="157.70"/>
                    <measurement group_id="O3" value="10.16" spread="107.21"/>
                    <measurement group_id="O4" value="3.99" spread="62.89"/>
                    <measurement group_id="O5" value="4.69" spread="90.75"/>
                    <measurement group_id="O6" value="1.89" spread="57.50"/>
                    <measurement group_id="O7" value="3.04" spread="89.37"/>
                    <measurement group_id="O8" value="6.83" spread="63.62"/>
                    <measurement group_id="O9" value="8.68" spread="98.54"/>
                    <measurement group_id="O10" value="4.59" spread="65.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD8-IFNγ] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.37" spread="84.04"/>
                    <measurement group_id="O2" value="9.19" spread="85.93"/>
                    <measurement group_id="O3" value="11.15" spread="94.57"/>
                    <measurement group_id="O4" value="2.18" spread="51.19"/>
                    <measurement group_id="O5" value="3.96" spread="75.52"/>
                    <measurement group_id="O6" value="2.03" spread="23.00"/>
                    <measurement group_id="O7" value="5.60" spread="50.57"/>
                    <measurement group_id="O8" value="3.18" spread="106.55"/>
                    <measurement group_id="O9" value="3.25" spread="64.56"/>
                    <measurement group_id="O10" value="1.59" spread="141.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD8-IFNγ] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.85" spread="103.62"/>
                    <measurement group_id="O2" value="3.95" spread="78.12"/>
                    <measurement group_id="O3" value="7.61" spread="309.89"/>
                    <measurement group_id="O4" value="2.46" spread="120.14"/>
                    <measurement group_id="O5" value="5.23" spread="75.71"/>
                    <measurement group_id="O6" value="2.51" spread="168.10"/>
                    <measurement group_id="O7" value="4.70" spread="53.61"/>
                    <measurement group_id="O8" value="4.05" spread="52.57"/>
                    <measurement group_id="O9" value="7.23" spread="129.33"/>
                    <measurement group_id="O10" value="7.26" spread="64.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD8-IFNγ] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.27" spread="78.96"/>
                    <measurement group_id="O2" value="8.63" spread="176.22"/>
                    <measurement group_id="O3" value="9.89" spread="295.99"/>
                    <measurement group_id="O4" value="3.52" spread="66.86"/>
                    <measurement group_id="O5" value="6.18" spread="125.90"/>
                    <measurement group_id="O6" value="10.28" spread="119.10"/>
                    <measurement group_id="O7" value="12.07" spread="140.10"/>
                    <measurement group_id="O8" value="4.02" spread="92.71"/>
                    <measurement group_id="O9" value="6.94" spread="109.72"/>
                    <measurement group_id="O10" value="2.21" spread="47.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD8-IFNγ] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.56" spread="99.28"/>
                    <measurement group_id="O2" value="10.71" spread="390.44"/>
                    <measurement group_id="O3" value="15.15" spread="261.46"/>
                    <measurement group_id="O4" value="6.09" spread="157.93"/>
                    <measurement group_id="O5" value="10.28" spread="61.17"/>
                    <measurement group_id="O6" value="1.69" spread="19.96"/>
                    <measurement group_id="O7" value="17.27" spread="129.27"/>
                    <measurement group_id="O8" value="17.76" spread="137.26"/>
                    <measurement group_id="O9" value="9.94" spread="190.65"/>
                    <measurement group_id="O10" value="9.07" spread="168.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD8-IFNγ] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.69" spread="129.41"/>
                    <measurement group_id="O2" value="17.80" spread="305.22"/>
                    <measurement group_id="O3" value="14.44" spread="160.52"/>
                    <measurement group_id="O4" value="5.42" spread="269.73"/>
                    <measurement group_id="O5" value="14.05" spread="224.41"/>
                    <measurement group_id="O6" value="9.75" spread="159.06"/>
                    <measurement group_id="O7" value="23.95" spread="323.71"/>
                    <measurement group_id="O8" value="18.53" spread="162.45"/>
                    <measurement group_id="O9" value="21.99" spread="122.96"/>
                    <measurement group_id="O10" value="12.44" spread="163.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD8-IL2] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.52" spread="80.50"/>
                    <measurement group_id="O2" value="3.10" spread="27.39"/>
                    <measurement group_id="O3" value="5.50" spread="55.47"/>
                    <measurement group_id="O4" value="3.03" spread="42.10"/>
                    <measurement group_id="O5" value="1.20" spread="13.14"/>
                    <measurement group_id="O6" value="2.12" spread="30.13"/>
                    <measurement group_id="O7" value="3.28" spread="81.61"/>
                    <measurement group_id="O8" value="2.96" spread="40.40"/>
                    <measurement group_id="O9" value="4.00" spread="42.26"/>
                    <measurement group_id="O10" value="2.67" spread="38.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD8-IL2] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" spread="63.95"/>
                    <measurement group_id="O2" value="4.30" spread="73.39"/>
                    <measurement group_id="O3" value="7.50" spread="51.96"/>
                    <measurement group_id="O4" value="3.97" spread="61.17"/>
                    <measurement group_id="O5" value="1.98" spread="40.41"/>
                    <measurement group_id="O6" value="4.86" spread="57.41"/>
                    <measurement group_id="O7" value="4.36" spread="36.32"/>
                    <measurement group_id="O8" value="5.57" spread="83.12"/>
                    <measurement group_id="O9" value="7.30" spread="69.21"/>
                    <measurement group_id="O10" value="2.17" spread="44.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD8-IL2] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" spread="113.92"/>
                    <measurement group_id="O2" value="3.21" spread="91.01"/>
                    <measurement group_id="O3" value="6.13" spread="99.85"/>
                    <measurement group_id="O4" value="3.13" spread="61.75"/>
                    <measurement group_id="O5" value="2.11" spread="71.74"/>
                    <measurement group_id="O6" value="4.05" spread="62.37"/>
                    <measurement group_id="O7" value="5.41" spread="65.29"/>
                    <measurement group_id="O8" value="6.43" spread="82.32"/>
                    <measurement group_id="O9" value="3.75" spread="71.92"/>
                    <measurement group_id="O10" value="2.00" spread="23.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD8-IL2] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.45" spread="89.54"/>
                    <measurement group_id="O2" value="5.93" spread="78.91"/>
                    <measurement group_id="O3" value="7.70" spread="64.46"/>
                    <measurement group_id="O4" value="3.05" spread="40.35"/>
                    <measurement group_id="O5" value="2.97" spread="61.70"/>
                    <measurement group_id="O6" value="4.41" spread="109.49"/>
                    <measurement group_id="O7" value="10.92" spread="109.83"/>
                    <measurement group_id="O8" value="6.18" spread="125.87"/>
                    <measurement group_id="O9" value="14.11" spread="81.52"/>
                    <measurement group_id="O10" value="2.69" spread="51.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD8-IL2] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.66" spread="147.36"/>
                    <measurement group_id="O2" value="4.40" spread="161.85"/>
                    <measurement group_id="O3" value="10.05" spread="141.49"/>
                    <measurement group_id="O4" value="9.50" spread="106.18"/>
                    <measurement group_id="O5" value="2.13" spread="22.15"/>
                    <measurement group_id="O6" value="2.66" spread="49.28"/>
                    <measurement group_id="O7" value="12.10" spread="182.42"/>
                    <measurement group_id="O8" value="17.14" spread="88.20"/>
                    <measurement group_id="O9" value="6.41" spread="108.44"/>
                    <measurement group_id="O10" value="2.17" spread="64.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD8-IL2] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.85" spread="257.14"/>
                    <measurement group_id="O2" value="32.92" spread="72.84"/>
                    <measurement group_id="O3" value="9.72" spread="118.83"/>
                    <measurement group_id="O4" value="4.83" spread="129.69"/>
                    <measurement group_id="O5" value="7.60" spread="27.90"/>
                    <measurement group_id="O6" value="8.49" spread="137.21"/>
                    <measurement group_id="O7" value="17.98" spread="127.27"/>
                    <measurement group_id="O8" value="5.19" spread="81.07"/>
                    <measurement group_id="O9" value="7.95" spread="75.16"/>
                    <measurement group_id="O10" value="12.46" spread="96.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD8-TNFα] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.41" spread="91.54"/>
                    <measurement group_id="O2" value="3.26" spread="34.12"/>
                    <measurement group_id="O3" value="8.71" spread="71.14"/>
                    <measurement group_id="O4" value="2.59" spread="42.20"/>
                    <measurement group_id="O5" value="2.58" spread="39.14"/>
                    <measurement group_id="O6" value="2.28" spread="45.26"/>
                    <measurement group_id="O7" value="2.18" spread="33.72"/>
                    <measurement group_id="O8" value="5.63" spread="58.18"/>
                    <measurement group_id="O9" value="3.94" spread="52.44"/>
                    <measurement group_id="O10" value="4.33" spread="81.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD8-TNFα] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" spread="79.93"/>
                    <measurement group_id="O2" value="12.15" spread="70.97"/>
                    <measurement group_id="O3" value="2.76" spread="117.87"/>
                    <measurement group_id="O4" value="5.85" spread="65.60"/>
                    <measurement group_id="O5" value="2.68" spread="61.45"/>
                    <measurement group_id="O6" value="3.78" spread="51.36"/>
                    <measurement group_id="O7" value="5.33" spread="36.95"/>
                    <measurement group_id="O8" value="6.03" spread="110.26"/>
                    <measurement group_id="O9" value="4.35" spread="64.50"/>
                    <measurement group_id="O10" value="1.91" spread="131.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD8-TNFα] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.04" spread="145.40"/>
                    <measurement group_id="O2" value="3.70" spread="138.04"/>
                    <measurement group_id="O3" value="5.31" spread="338.73"/>
                    <measurement group_id="O4" value="3.70" spread="67.70"/>
                    <measurement group_id="O5" value="8.64" spread="86.13"/>
                    <measurement group_id="O6" value="9.54" spread="187.33"/>
                    <measurement group_id="O7" value="5.96" spread="128.54"/>
                    <measurement group_id="O8" value="10.06" spread="78.63"/>
                    <measurement group_id="O9" value="3.93" spread="93.43"/>
                    <measurement group_id="O10" value="3.41" spread="64.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD8-TNFα] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.64" spread="98.80"/>
                    <measurement group_id="O2" value="5.75" spread="118.21"/>
                    <measurement group_id="O3" value="5.74" spread="278.42"/>
                    <measurement group_id="O4" value="3.47" spread="65.17"/>
                    <measurement group_id="O5" value="5.60" spread="66.01"/>
                    <measurement group_id="O6" value="12.32" spread="188.66"/>
                    <measurement group_id="O7" value="11.29" spread="211.80"/>
                    <measurement group_id="O8" value="8.52" spread="135.47"/>
                    <measurement group_id="O9" value="16.28" spread="142.20"/>
                    <measurement group_id="O10" value="2.52" spread="46.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD8-TNFα] at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.49" spread="167.40"/>
                    <measurement group_id="O2" value="11.28" spread="215.17"/>
                    <measurement group_id="O3" value="18.47" spread="194.16"/>
                    <measurement group_id="O4" value="8.77" spread="177.85"/>
                    <measurement group_id="O5" value="6.77" spread="50.82"/>
                    <measurement group_id="O6" value="2.67" spread="37.22"/>
                    <measurement group_id="O7" value="26.25" spread="172.19"/>
                    <measurement group_id="O8" value="23.27" spread="109.52"/>
                    <measurement group_id="O9" value="14.97" spread="169.37"/>
                    <measurement group_id="O10" value="9.07" spread="123.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD8-TNFα] at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.50" spread="261.61"/>
                    <measurement group_id="O2" value="13.76" spread="122.97"/>
                    <measurement group_id="O3" value="9.28" spread="142.76"/>
                    <measurement group_id="O4" value="9.21" spread="224.57"/>
                    <measurement group_id="O5" value="15.20" spread="160.37"/>
                    <measurement group_id="O6" value="9.02" spread="96.93"/>
                    <measurement group_id="O7" value="27.84" spread="355.89"/>
                    <measurement group_id="O8" value="15.64" spread="126.07"/>
                    <measurement group_id="O9" value="19.42" spread="124.13"/>
                    <measurement group_id="O10" value="8.57" spread="151.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180</title>
        <description>The markers assessed were CD8-All doubles, CD8-CD40L, CD8-IFNγ, CD8-IL2 and CD8-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
        <time_frame>At Day 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence for cell mediated immunity (CMI) which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available at day 180.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180</title>
          <description>The markers assessed were CD8-All doubles, CD8-CD40L, CD8-IFNγ, CD8-IL2 and CD8-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence for cell mediated immunity (CMI) which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available at day 180.</population>
          <units>cells per million CD8 T-cells</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="19"/>
                <count group_id="O8" value="16"/>
                <count group_id="O9" value="16"/>
                <count group_id="O10" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands [CD8-All doubles]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="89.78"/>
                    <measurement group_id="O2" value="14.64" spread="96.62"/>
                    <measurement group_id="O3" value="3.61" spread="143.10"/>
                    <measurement group_id="O4" value="4.75" spread="74.09"/>
                    <measurement group_id="O5" value="3.05" spread="107.06"/>
                    <measurement group_id="O6" value="1.24" spread="15.43"/>
                    <measurement group_id="O7" value="2.64" spread="47.18"/>
                    <measurement group_id="O8" value="4.81" spread="90.76"/>
                    <measurement group_id="O9" value="7.32" spread="115.74"/>
                    <measurement group_id="O10" value="5.64" spread="98.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD8-All doubles]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.14" spread="506.65"/>
                    <measurement group_id="O2" value="9.63" spread="110.40"/>
                    <measurement group_id="O3" value="18.10" spread="367.31"/>
                    <measurement group_id="O4" value="16.14" spread="132.83"/>
                    <measurement group_id="O5" value="20.72" spread="412.35"/>
                    <measurement group_id="O6" value="21.73" spread="368.70"/>
                    <measurement group_id="O7" value="21.00" spread="327.24"/>
                    <measurement group_id="O8" value="11.95" spread="384.28"/>
                    <measurement group_id="O9" value="10.44" spread="226.57"/>
                    <measurement group_id="O10" value="3.13" spread="186.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD8-All doubles]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.92" spread="111.75"/>
                    <measurement group_id="O2" value="7.10" spread="132.35"/>
                    <measurement group_id="O3" value="12.14" spread="319.23"/>
                    <measurement group_id="O4" value="9.61" spread="157.68"/>
                    <measurement group_id="O5" value="25.48" spread="138.45"/>
                    <measurement group_id="O6" value="9.18" spread="143.21"/>
                    <measurement group_id="O7" value="12.73" spread="460.97"/>
                    <measurement group_id="O8" value="4.71" spread="115.31"/>
                    <measurement group_id="O9" value="6.47" spread="83.62"/>
                    <measurement group_id="O10" value="7.96" spread="132.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD8-CD40L]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92" spread="53.08"/>
                    <measurement group_id="O2" value="12.64" spread="119.84"/>
                    <measurement group_id="O3" value="2.95" spread="97.98"/>
                    <measurement group_id="O4" value="3.18" spread="74.24"/>
                    <measurement group_id="O5" value="3.97" spread="69.10"/>
                    <measurement group_id="O6" value="1.93" spread="31.31"/>
                    <measurement group_id="O7" value="2.70" spread="59.56"/>
                    <measurement group_id="O8" value="4.89" spread="86.67"/>
                    <measurement group_id="O9" value="8.74" spread="100.11"/>
                    <measurement group_id="O10" value="3.94" spread="40.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD8-CD40L]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.75" spread="312.61"/>
                    <measurement group_id="O2" value="7.79" spread="60.25"/>
                    <measurement group_id="O3" value="10.73" spread="230.49"/>
                    <measurement group_id="O4" value="15.32" spread="145.70"/>
                    <measurement group_id="O5" value="9.60" spread="232.78"/>
                    <measurement group_id="O6" value="8.57" spread="321.14"/>
                    <measurement group_id="O7" value="13.90" spread="118.80"/>
                    <measurement group_id="O8" value="6.00" spread="315.87"/>
                    <measurement group_id="O9" value="6.46" spread="135.88"/>
                    <measurement group_id="O10" value="3.43" spread="66.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD8-CD40L]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.79" spread="103.71"/>
                    <measurement group_id="O2" value="5.64" spread="75.90"/>
                    <measurement group_id="O3" value="10.61" spread="125.46"/>
                    <measurement group_id="O4" value="7.48" spread="92.38"/>
                    <measurement group_id="O5" value="8.46" spread="105.02"/>
                    <measurement group_id="O6" value="6.10" spread="113.43"/>
                    <measurement group_id="O7" value="3.77" spread="59.02"/>
                    <measurement group_id="O8" value="2.75" spread="73.05"/>
                    <measurement group_id="O9" value="3.63" spread="81.37"/>
                    <measurement group_id="O10" value="3.78" spread="95.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD8-IFNγ]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="54.66"/>
                    <measurement group_id="O2" value="3.12" spread="124.76"/>
                    <measurement group_id="O3" value="3.13" spread="50.16"/>
                    <measurement group_id="O4" value="3.89" spread="53.23"/>
                    <measurement group_id="O5" value="1.90" spread="35.38"/>
                    <measurement group_id="O6" value="3.12" spread="47.02"/>
                    <measurement group_id="O7" value="3.07" spread="31.51"/>
                    <measurement group_id="O8" value="3.11" spread="45.39"/>
                    <measurement group_id="O9" value="2.36" spread="55.08"/>
                    <measurement group_id="O10" value="2.65" spread="79.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD8-IFNγ]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" spread="167.18"/>
                    <measurement group_id="O2" value="2.68" spread="42.60"/>
                    <measurement group_id="O3" value="2.32" spread="92.50"/>
                    <measurement group_id="O4" value="2.89" spread="43.98"/>
                    <measurement group_id="O5" value="2.50" spread="53.46"/>
                    <measurement group_id="O6" value="2.53" spread="46.46"/>
                    <measurement group_id="O7" value="2.39" spread="154.17"/>
                    <measurement group_id="O8" value="3.67" spread="78.90"/>
                    <measurement group_id="O9" value="1.97" spread="157.41"/>
                    <measurement group_id="O10" value="2.72" spread="125.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD8-IFNγ]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.63" spread="76.06"/>
                    <measurement group_id="O2" value="3.72" spread="66.40"/>
                    <measurement group_id="O3" value="6.46" spread="183.07"/>
                    <measurement group_id="O4" value="6.19" spread="170.54"/>
                    <measurement group_id="O5" value="10.24" spread="49.87"/>
                    <measurement group_id="O6" value="4.96" spread="55.70"/>
                    <measurement group_id="O7" value="8.54" spread="430.43"/>
                    <measurement group_id="O8" value="2.56" spread="40.61"/>
                    <measurement group_id="O9" value="4.12" spread="49.87"/>
                    <measurement group_id="O10" value="5.33" spread="182.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD8-IL2]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="64.78"/>
                    <measurement group_id="O2" value="10.49" spread="74.37"/>
                    <measurement group_id="O3" value="2.82" spread="105.05"/>
                    <measurement group_id="O4" value="3.36" spread="44.53"/>
                    <measurement group_id="O5" value="3.76" spread="68.56"/>
                    <measurement group_id="O6" value="1.89" spread="25.49"/>
                    <measurement group_id="O7" value="4.31" spread="70.92"/>
                    <measurement group_id="O8" value="4.89" spread="86.67"/>
                    <measurement group_id="O9" value="4.93" spread="111.36"/>
                    <measurement group_id="O10" value="7.15" spread="75.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD8-IL2]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.60" spread="427.25"/>
                    <measurement group_id="O2" value="15.24" spread="108.11"/>
                    <measurement group_id="O3" value="14.05" spread="351.12"/>
                    <measurement group_id="O4" value="42.75" spread="112.35"/>
                    <measurement group_id="O5" value="19.37" spread="415.28"/>
                    <measurement group_id="O6" value="32.48" spread="357.67"/>
                    <measurement group_id="O7" value="15.96" spread="296.44"/>
                    <measurement group_id="O8" value="11.89" spread="385.26"/>
                    <measurement group_id="O9" value="10.37" spread="212.91"/>
                    <measurement group_id="O10" value="4.04" spread="153.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD8-IL2]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" spread="92.98"/>
                    <measurement group_id="O2" value="7.59" spread="100.66"/>
                    <measurement group_id="O3" value="11.05" spread="217.46"/>
                    <measurement group_id="O4" value="7.47" spread="77.13"/>
                    <measurement group_id="O5" value="11.50" spread="130.60"/>
                    <measurement group_id="O6" value="11.62" spread="176.05"/>
                    <measurement group_id="O7" value="3.86" spread="81.13"/>
                    <measurement group_id="O8" value="5.99" spread="110.92"/>
                    <measurement group_id="O9" value="4.38" spread="95.85"/>
                    <measurement group_id="O10" value="6.11" spread="91.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [CD8-TNFα]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" spread="60.55"/>
                    <measurement group_id="O2" value="2.35" spread="31.14"/>
                    <measurement group_id="O3" value="2.09" spread="62.82"/>
                    <measurement group_id="O4" value="3.60" spread="37.07"/>
                    <measurement group_id="O5" value="1.62" spread="76.42"/>
                    <measurement group_id="O6" value="1.53" spread="21.24"/>
                    <measurement group_id="O7" value="2.44" spread="28.80"/>
                    <measurement group_id="O8" value="2.73" spread="44.50"/>
                    <measurement group_id="O9" value="2.54" spread="79.84"/>
                    <measurement group_id="O10" value="3.39" spread="69.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [CD8-TNFα]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.78" spread="244.26"/>
                    <measurement group_id="O2" value="4.42" spread="63.49"/>
                    <measurement group_id="O3" value="9.25" spread="151.69"/>
                    <measurement group_id="O4" value="6.69" spread="85.85"/>
                    <measurement group_id="O5" value="6.67" spread="210.64"/>
                    <measurement group_id="O6" value="3.26" spread="108.02"/>
                    <measurement group_id="O7" value="9.09" spread="213.44"/>
                    <measurement group_id="O8" value="4.86" spread="78.63"/>
                    <measurement group_id="O9" value="6.81" spread="139.38"/>
                    <measurement group_id="O10" value="3.52" spread="125.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [CD8-TNFα]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.05" spread="74.16"/>
                    <measurement group_id="O2" value="5.66" spread="88.74"/>
                    <measurement group_id="O3" value="14.08" spread="191.59"/>
                    <measurement group_id="O4" value="3.84" spread="93.04"/>
                    <measurement group_id="O5" value="6.11" spread="48.41"/>
                    <measurement group_id="O6" value="5.46" spread="88.95"/>
                    <measurement group_id="O7" value="5.07" spread="415.90"/>
                    <measurement group_id="O8" value="3.63" spread="81.27"/>
                    <measurement group_id="O9" value="4.69" spread="42.36"/>
                    <measurement group_id="O10" value="4.58" spread="132.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</title>
        <description>Grade 3 ecchymosis, pain, redness and swelling was greater than 100 millimeter (mm) i.e. &gt; 100 mm and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade. Any for ecchymosis, redness and swelling was &gt;20mm.</description>
        <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</title>
          <description>Grade 3 ecchymosis, pain, redness and swelling was greater than 100 millimeter (mm) i.e. &gt; 100 mm and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade. Any for ecchymosis, redness and swelling was &gt;20mm.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="201"/>
                <count group_id="O5" value="198"/>
                <count group_id="O6" value="197"/>
                <count group_id="O7" value="198"/>
                <count group_id="O8" value="198"/>
                <count group_id="O9" value="200"/>
                <count group_id="O10" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="111"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="91"/>
                    <measurement group_id="O6" value="119"/>
                    <measurement group_id="O7" value="93"/>
                    <measurement group_id="O8" value="106"/>
                    <measurement group_id="O9" value="32"/>
                    <measurement group_id="O10" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="36"/>
                    <measurement group_id="O7" value="18"/>
                    <measurement group_id="O8" value="34"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="25"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Solicited Local AEs</title>
        <description>Duration was defined as number of days with any grade of local symptoms.</description>
        <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom and completed information on duration in their symptom sheet.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited Local AEs</title>
          <description>Duration was defined as number of days with any grade of local symptoms.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom and completed information on duration in their symptom sheet.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="111"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="119"/>
                <count group_id="O7" value="93"/>
                <count group_id="O8" value="106"/>
                <count group_id="O9" value="32"/>
                <count group_id="O10" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ecchymosis (N=3;1;5;1;2;2;4;2;3;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="6.0" lower_limit="6.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="6.0" lower_limit="3.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="2.0" upper_limit="2.0"/>
                    <measurement group_id="O5" value="2.5" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O6" value="3.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O7" value="3.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O8" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O9" value="5.0" lower_limit="4.0" upper_limit="7.0"/>
                    <measurement group_id="O10" value="NA">None of the subjects in this group reported any ecchymosis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (N=68;82;111;84;91;119;93;106;32;93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O7" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O8" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O9" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O10" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness (N=14;16;35;11;33;36;18;34;5;2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O6" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O7" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O8" value="3.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O9" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O10" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (N=12;12;24;12;17;23;11;25;5;2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="2.5" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O6" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O7" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O8" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O9" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O10" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</title>
        <description>Any Fever was defined as axillary temperature greater than or equal to 38.0 degree centigrade i.e.≥ 38.0°C, grade 3 fever was axillary temperature &gt;40°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a general symptom that prevented normal activity. Related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</title>
          <description>Any Fever was defined as axillary temperature greater than or equal to 38.0 degree centigrade i.e.≥ 38.0°C, grade 3 fever was axillary temperature &gt;40°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a general symptom that prevented normal activity. Related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="201"/>
                <count group_id="O5" value="198"/>
                <count group_id="O6" value="198"/>
                <count group_id="O7" value="198"/>
                <count group_id="O8" value="198"/>
                <count group_id="O9" value="200"/>
                <count group_id="O10" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="45"/>
                    <measurement group_id="O7" value="28"/>
                    <measurement group_id="O8" value="35"/>
                    <measurement group_id="O9" value="16"/>
                    <measurement group_id="O10" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="25"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="46"/>
                    <measurement group_id="O6" value="55"/>
                    <measurement group_id="O7" value="38"/>
                    <measurement group_id="O8" value="63"/>
                    <measurement group_id="O9" value="24"/>
                    <measurement group_id="O10" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="38"/>
                    <measurement group_id="O7" value="25"/>
                    <measurement group_id="O8" value="35"/>
                    <measurement group_id="O9" value="16"/>
                    <measurement group_id="O10" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="55"/>
                    <measurement group_id="O7" value="36"/>
                    <measurement group_id="O8" value="48"/>
                    <measurement group_id="O9" value="23"/>
                    <measurement group_id="O10" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="27"/>
                    <measurement group_id="O9" value="20"/>
                    <measurement group_id="O10" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="66"/>
                    <measurement group_id="O7" value="46"/>
                    <measurement group_id="O8" value="56"/>
                    <measurement group_id="O9" value="19"/>
                    <measurement group_id="O10" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="46"/>
                    <measurement group_id="O7" value="34"/>
                    <measurement group_id="O8" value="44"/>
                    <measurement group_id="O9" value="15"/>
                    <measurement group_id="O10" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="14"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="43"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="31"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="21"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Solicited General AEs</title>
        <description>Duration was defined as number of days with any grade of general symptoms.</description>
        <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom and completed information on duration in their symptom sheet.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited General AEs</title>
          <description>Duration was defined as number of days with any grade of general symptoms.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom and completed information on duration in their symptom sheet.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="66"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="63"/>
                <count group_id="O9" value="24"/>
                <count group_id="O10" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia (N=15;23;36;16;21;45;28;35;16;12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O7" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O8" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O9" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O10" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=34;35;54;35;46;55;38;63;24;41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O7" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O8" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O9" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O10" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=22;38;47;35;39;55;36;48;23;45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O7" value="1.5" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O8" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O9" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O10" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=20;35;57;30;47;66;46;56;19;40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O7" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O8" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O9" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O10" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (N=10;12;19;10;13;18;8;14;6;13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O6" value="1.5" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O7" value="1.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O8" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O9" value="1.5" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O10" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering (N=13;18;37;26;18;43;17;31;8;21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O6" value="1.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O7" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O8" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O9" value="2.5" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O10" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (N=4;3;9;4;3;14;6;12;0;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="3.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O4" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O6" value="1.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O7" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O8" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O9" value="NA">None of the subjects in this group reported any fever.</measurement>
                    <measurement group_id="O10" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.</description>
        <time_frame>During a 21-day follow-up period (Day 0-20) after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="199"/>
                <count group_id="O6" value="198"/>
                <count group_id="O7" value="198"/>
                <count group_id="O8" value="199"/>
                <count group_id="O9" value="200"/>
                <count group_id="O10" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="42"/>
                    <measurement group_id="O7" value="34"/>
                    <measurement group_id="O8" value="43"/>
                    <measurement group_id="O9" value="27"/>
                    <measurement group_id="O10" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20</title>
        <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a symptom that prevented normal activity. Related was a symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Between Day 0 and Day 20 after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20</title>
          <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a symptom that prevented normal activity. Related was a symptom assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="199"/>
                <count group_id="O6" value="198"/>
                <count group_id="O7" value="198"/>
                <count group_id="O8" value="199"/>
                <count group_id="O9" value="200"/>
                <count group_id="O10" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(S)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179</title>
        <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a symptom that prevented normal activity. Related was a symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Between Day 21 and Day 179 after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179</title>
          <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a symptom that prevented normal activity. Related was a symptom assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="199"/>
                <count group_id="O6" value="198"/>
                <count group_id="O7" value="198"/>
                <count group_id="O8" value="199"/>
                <count group_id="O9" value="200"/>
                <count group_id="O10" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE (s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="79"/>
                    <measurement group_id="O4" value="71"/>
                    <measurement group_id="O5" value="65"/>
                    <measurement group_id="O6" value="67"/>
                    <measurement group_id="O7" value="67"/>
                    <measurement group_id="O8" value="69"/>
                    <measurement group_id="O9" value="69"/>
                    <measurement group_id="O10" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="15"/>
                    <measurement group_id="O9" value="17"/>
                    <measurement group_id="O10" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Between Day 0 and Day 20 after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="199"/>
                <count group_id="O6" value="198"/>
                <count group_id="O7" value="198"/>
                <count group_id="O8" value="199"/>
                <count group_id="O9" value="200"/>
                <count group_id="O10" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Between Day 21 and Day 179 after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O4">
            <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O5">
            <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O6">
            <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O7">
            <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O8">
            <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
            <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
          </group>
          <group group_id="O9">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O10">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="199"/>
                <count group_id="O6" value="198"/>
                <count group_id="O7" value="198"/>
                <count group_id="O8" value="199"/>
                <count group_id="O9" value="200"/>
                <count group_id="O10" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="19"/>
                    <measurement group_id="O9" value="15"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.</time_frame>
      <desc>For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Influenza Vaccine GSK576389A Formulation 1 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="E2">
          <title>Influenza Vaccine GSK576389A Formulation 2 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="E3">
          <title>Influenza Vaccine GSK576389A Formulation 3 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="E4">
          <title>Influenza Vaccine GSK576389A Formulation 4 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="E5">
          <title>Influenza Vaccine GSK576389A Formulation 5 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="E6">
          <title>Influenza Vaccine GSK576389A Formulation 6 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="E7">
          <title>Influenza Vaccine GSK576389A Formulation 7 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="E8">
          <title>Influenza Vaccine GSK576389A Formulation 8 Group</title>
          <description>Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.</description>
        </group>
        <group group_id="E9">
          <title>Fluarix Elderly Group</title>
          <description>Subjects aged ≥65 years received one dose of Fluarix vaccine.</description>
        </group>
        <group group_id="E10">
          <title>Fluarix Young Group</title>
          <description>Subjects aged 18-40 years received one dose of Fluarix vaccine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Bifascicular block</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Hypertensive cardiomyopathy</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Chronic myelomonocytic leukaemia</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Neuritis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Reversible ischaemic neurological deficit</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <description>Assessed between Day 0 and Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Bleeding varicose vein</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <description>Assessed between Day 21 and Day 179</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="111" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="84" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="91" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="119" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="93" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="106" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="32" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="93" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="111" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="84" subjects_at_risk="201"/>
                <counts group_id="E5" subjects_affected="91" subjects_at_risk="198"/>
                <counts group_id="E6" subjects_affected="119" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="93" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="106" subjects_at_risk="198"/>
                <counts group_id="E9" subjects_affected="32" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="93" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="201"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="198"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="34" subjects_at_risk="198"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="201"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="198"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="25" subjects_at_risk="198"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="201"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="198"/>
                <counts group_id="E6" subjects_affected="45" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="28" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="35" subjects_at_risk="198"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="12" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="201"/>
                <counts group_id="E5" subjects_affected="46" subjects_at_risk="198"/>
                <counts group_id="E6" subjects_affected="55" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="38" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="63" subjects_at_risk="198"/>
                <counts group_id="E9" subjects_affected="24" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="41" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="201"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="198"/>
                <counts group_id="E6" subjects_affected="55" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="36" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="48" subjects_at_risk="198"/>
                <counts group_id="E9" subjects_affected="23" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="45" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="201"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="198"/>
                <counts group_id="E6" subjects_affected="66" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="46" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="56" subjects_at_risk="198"/>
                <counts group_id="E9" subjects_affected="19" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="40" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="201"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="198"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="198"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="201"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="198"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="31" subjects_at_risk="198"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="21" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="198"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="199"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

